CURRICULUM VITAE

 

Dr Hani El-Gabalawy MD FRCPC

University of Manitoba Arthritis Centre

RR149-800 Sherbrook Street

Winnipeg, Manitoba, Canada, R3A 1M4

tel        (204) 787-2208 (academic)

            (204) 318-2550 (CIHR)

fax       (204) 787-2475

email: hani.elgabalawy@umanitoba.ca

CURRENT POSITIONS

Scientific Director for the CIHR - Institute of Musculoskeletal Health and Arthritis (IMHA)

Professor of Medicine and Immunology

Endowed Rheumatology Research Chair

University of Manitoba

 

DEMOGRAPHIC INFORMATION

Date of birth: 13 July 1954

Citizenship:    Canadian

Spouse:          Married, Alda Butland

Children:        Nadia, Renee, Adam

Languages spoken: English, French, and Arabic

 

EDUCATION AND TRAINING

_      Pre-medical Studies: Faculty of Science, University of Calgary 1971-1974

_      Medical Studies: Faculty of Medicine, University of Calgary 1974-1977

_      Rotating Internship: Faculty of Medicine, Dalhousie University 1977-1978

_      R1 Internal Medicine: Faculty of Medicine, Dalhousie University 1978-1979

_      R2, R3 Internal Medicine: Faculty of Medicine, McGill University 1980-1982

_      Rheumatology Fellow: Faculty of Medicine, McGill University 1982-1984

 

DEGREES AND FELLOWSHIP CERTIFICATION

_      BSc University of Calgary 1974

_      MD University of Calgary 1977

_      FRCPC Internal Medicine 1983

_      FRCPC Rheumatology 1984

_      Specialty Certificate Province of Quebec: Rheumatology 1984

_      American Board of Internal Medicine: Rheumatology 1984

 

PROFESSIONAL HISTORY

Fredericton, New Brunswick, Canada, 1984-1990

_      Consultant in Rheumatology, Fredericton Medical Clinic: 1984-1990

_      Attending physician, Rheumatology and Internal Medicine, Dr. Everett Chalmers Hospital, Fredericton: 1984-1990

_      Clinical Instructor, Dalhousie University: 1985-1990

_      Lecturer in Immunology, University of New Brunswick: 1987-1990

_      Head, Department of Internal Medicine and member of the Medical Advisory Committee,

      Dr. Everett Chalmers Hospital, Fredericton, New Brunswick, Canada: 1988-1990

_      Coordinator, AIDS Clinical Management Program, Province of New Brunswick: 1988-1990

 

University of Manitoba, Winnipeg, Manitoba, Canada, 1990-Present

_      Assistant Professor, Department of Internal Medicine, University of Manitoba: 1990-1995

_      Director, Postgraduate Program in Rheumatology, University of Manitoba: 1994-1996

_      Associate Professor, Department of Internal Medicine, University of Manitoba: 1995-2000

_      Head, Section of Rheumatology, University of Manitoba, Director, Arthritis Centre: 1995-2010

_      Clinical Director, Rheumatic Diseases Research Laboratory, University of Manitoba:2000- present

_      Professor, Department of Internal Medicine, University of Manitoba: 2000-present

_      Professor, Department of Immunology, University of Manitoba: 2004-present

_      Endowed Rheumatology Research Chair, University of Manitoba: 2003-present

 

Arthritis and Rheumatism Branch, National Institute of Arthritis Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland, 1998-2000

_      Visiting Scientist: Principal Investigator, Early Synovitis Studies: 1998-2000

_      Associate Program Director, Rheumatology: 1998-2000

 

Division of Rheumatology, University of Toronto, Toronto, January 2009-March 2009

_      Visiting Scientist

 

Department of Rheumatology, Leiden University, The Netherlands, April 2009-June 2009

_      Visiting Scientist

 

PROFESSIONAL MEMBERSHIPS AND ASSOCIATIONS

_      Royal College of Physicians and Surgeons of Canada

_      College of Physicians and Surgeons of MB

_      Canadian Medical Association

_      Canadian Rheumatology Association

_      Manitoba Medical Association

_      American College of Rheumatology

_      Washington DC Rheumatism Association

_      Arthritis Foundation, USA

_      The British Society for Rheumatology

 

PROFESSIONAL ACTIVITIES AND COMMITTEE MEMBERSHIPS

_      Grants review panel, Terry Fox Research Fund of New Brunswick, 1989

_      Grants review panel, New Brunswick Medical Research Fund, 1989

_      Medical Advisory Committee, Dr Everett Chalmers Hospital, Fredericton, 1988-1990

_      Finance Committee, Department of Medicine, University of Manitoba, 1994-1998

_      Rheumatology Subspecialty Committee, Royal College of Physicians and Surgeons of Canada

_      Grant reviews panel, Immunology, Arthritis Society of Canada, Toronto 1996

_      Rheumatic Disease Unit Council of Canada, 1995-present

_      Vice-Chair, Rheumatology Examinations Board, Royal College of Physicians and Surgeons of Canada, 1998-2001

_      Chair, Rheumatology Examinations Board, Royal College of Physicians and Surgeons of Canada, 2001-2003

_      Training award review panel, Canadian Arthritis Network (CAN), 2001-present

_      Personnel Review Committee, Manitoba Health Research Council, 2001

_      Vice Chair, Canadian Council of Academic Rheumatologists (CCAR), 2001-2003

_      Diagnostics & Therapeutics Theme leader, Canadian Arthritis Network, 2002-2004

_      Medical Advisory Committee (MAC), The Arthritis Society National Office (TAS), 2002-2004

_      Research Advisory Committee (RAC), Canadian Arthritis Network, 2002-2007

_      Chair, Canadian Council of Academic Rheumatologists (CCAR), 2003-2005

_      Co-chair, Frontiers in Inflammatory Joint Diseases in Canada, Consensus Conference, 2003 – proceedings published as a supplement to the Journal of Rheumatology, January 2005

_      Associate Editor, Global Arthritis Research Network, 2003-2006

_      Management Committee, Canadian Arthritis Network, 2003-2007

_      CIHR, Grant Committee Member, Clinical Investigation “B” Committee 2004-2008, 2010

_      Chair, Abstract Review Committee, RA Clinical Studies, American College of Rheumatology 2005, 2006.

_      Member, Institutional Advisory Board, Institute of Musculoskeletal Health and Arthritis, CIHR, 2005-2008

_      Chair, Promotions Committee, Department of Int. Medicine, University of Manitoba, 2006-2008

_      Chair, International Symposium on Rheumatic Diseases in Indigenous Populations: from molecules to communities, Winnipeg, Sept 24-25, 2009 – Symposium report submitted to CIHR and Canadian Arthritis Network, publication in progress.

_      Co-Chair, "Symposium 1: Genetic Discoveries that will change the way we manage Inflammatory Autoimmune Diseases", Annual Scientific Conference, Canadian Arthritis Network, Vancouver, Nov 20, 2009

_      Member, Faculty Development Committee, Department of Internal Medicine, University of Manitoba, 2005-present

_      Co-Chair, Rheumatoid Arthritis in First Nations:  Defining the road toward disease prevention, Winnipeg, October 4-5, 2012

 

OTHER PROFESSIONAL ACTIVITIES

 

Editorial Boards

Associate Editor, Arthritis and Rheumatism

Journal of Rheumatology

Rheumatology

 

Manuscript reviewer

_      Arthritis and Rheumatism

_      Journal of Rheumatology

_      Rheumatology (Oxford)

_      Canadian Medical Association Journal

_      Annals of Rheumatic Diseases

_      Arthritis Research and Therapy

_      Nature Reviews

 

Pharmaceutical Advisory Board memberships:

_      Merck-Frosst

_      MedImmune

_      GlaxoSmithKline

_      Hoffman-LaRoche

_      Schering

_      Abbott

_      Bristol Myers Squibb

 
AWARDS AND DISTINCTIONS

_      NIH Clinical Center, Bench to Bedside Award, 1999

_      Jeff Shiroky Memorial Prize in Rheumatology, 2000

_      Endowed Rheumatology Research Chair, 2003-present

_      Pfizer Visiting Professorship, University of Texas, Dallas, 2007

_      Post-graduate teaching award, Department of Internal Medicine, 2009

_      Member, Henry Kunkel Society, Rockefeller University, New York, 2010

_      Fellowship in the Canadian Academy of Health Sciences (CAHS), Ottawa 2010

_      Queen Elizabeth II Diamond Jubilee Medal, Ottawa, 2013

_      CRA Distinguished Investigator Award, Quebec City, 2015

 

RESEARCH GRANTS AND PROTOCOLS

 

Principal Investigator

_      New Brunswick Medical Research Fund. "A longitudinal study of soluble IL2 receptor levels in patients with rheumatoid arthritis". $30,000 (1989-1990).

 

_      Health Sciences Centre Foundation. "Evolution of pathological synovial cell phenotypes in rheumatoid synovitis".  $40,000 (1994-1995).

 

_      Health Sciences Centre Foundation.  "Characterization of Synovial Cell Phenotype during the Course of Rheumatoid Arthritis". $43,000 (1995-1996).

 

_      The Thorlakson Foundation. “Assessment of the biological and clinical effects of antioxidant vitamin supplementation in patients with rheumatoid arthritis”. $18,000 (1997-1998)

 

_      Pathogenesis of Inflammatory Synovitis: A Study of Early Arthritis. NIH protocol 94-AR-0194 Intramural Research Program, $100,000/yr USD (estimated), (1998-2000)

 

_      Prognostic Indicators and Determinants of the 2-5 year outcome in a cohort of early synovitis patients. NIH protocol 98-AR-0150, Intramural Research Program $100,000/yr USD (estimated), (1998-2000)

 

_      H215O Positron Emission Tomography (PET) in the assessment of synovial vascularity and blood flow in rheumatoid arthritis patients NIH protocol 00-AR-0061, Intramural Research Program, $40,000 USD (estimated), (2000-2001)

 

_      NIH Clinical Center Bench to Bedside award. “Inhibition of angiogenesis in severe, early RA”, $100,000/yr US funds (1999-2000)

 

_      University of Manitoba. “Prevention of bone erosions in rheumatoid arthritis. A biological based approach for assessing the impact of targeted therapy, $50,000 (2000-2001)

 

_      CIHR/RPP. “Synovial cell responses to hypoxia: Potential role in the pathogenesis and persistence of inflammatory arthritis, $89,960/year (2001-2003)

 

_      NIH/National Institute of Allergy and Infectious Diseases Funds. “HLA microsatellite associations in aboriginal Canadian patients with rheumatoid arthritis”, $164,050 USD, University of Manitoba supplement to R01 AI45659-03, Dr Lee Nelson Principal Investigator (2002-2004)

 

_      Cardion Pharmaceuticals Inc. “Evaluation of Depletin, an IL-15 inhibitor, using RA synovial tissue engrafted into a SCID mouse model” $32,704 USD  (2002-2003)

 

_      Canadian Arthritis Network. “Osteoclastic resorption in inflammatory arthritis:  Regulation of osteoclasts and angiogenesis by the avb3 integrin blocker Vitaxin” Co-Principal Investigator, with Dr Jeff Dixon, $83,000 (2002-2003)

 

_      Cardion Pharmaceuticals, Inc.  “Efficacy in Depletin in an RA – SCID Model”,  $51,999 (2002-2003)

 

_      Medimmune Inc.  “Evaluation of effects of Vitaxin on human synovial Tissue”, $64,763 (2003-2004)

 

_      Canadian Arthritis Network. “Synovial outcomes in rheumatoid arthritis therapy” Co-investigators Drs. Ed Keystone, Paul Haraoui, John Wilkins, Michael Centola $121,000/yr $242,000 (2003-2005).

 

_      The Arthritis Society. “Synovial cell responses to hypoxia: potential role in the pathogenesis and persistence of inflammatory arthritis.  $98,280/yr $294,840 (2003-2006)

 

_      Medimmune Inc. “Evaluation of Effects of Vitaxin on Human Synovial Tissues” $47,620 USD (2003-2004)

 

_      Medimmune Inc.  “Evaluation of effects of Vitaxin on human synovial tissues” $38,572 (2004)

 

 

_      Networks for Centres of Excellence (NCE).  “Synovial outcomes in rheumatoid arthritis therapy”, $243,000 (2003-2005)

 

_      The Arthritis Society.  “Synovial cell responses to hypoxia:  Potential role in the pathogenesis and persistence of inflammatory arthritis”, $294,840  (2003-2006)

 

_      Canadian Arthritis Network. “Synovitis in early RA:  A bench to bedside Approach” $130,000 (2005-2006)

 

_      Networks of Centres of Excellence (NCE).  “Synovitis in early RA:  A bedside to bench approach”,  $130,000 (2005-2006)

 

_      Canadian Institutes of Health Research.  “Early Identification of Rheumatoid Arthritis in Canadian First Nations” $404,220 (2005-2008)

 

_      Networks of Centres of Excellence (NCE).  “Treatment of DMARD naēve patients with poor prognosis rheumatoid arthritis using rituximab:  a pilot study evaluating synovial outcomes” $225,000 (2007-2009)

 

_      AstraZeneca.  “The evolution of early Rheumatoid Arthritis:  An integrated approach to predicting disease course $518,700 (2007-2010)

 

_      Canadian Initiative for Outcomes in Rheumatology cAre (CIORA).  “Capacity Building for Knowledge exchange in RA Detection and Prevention Studies at First Nation Communities" ethics # H2012:024 Aim 1 and Aim 2 ethics # H2012:094, $60,000.00 (January 2012)

 

_      Canadian Institutes of Health Research.  Risk for RA in First Nations Populations”, Rheumatoid Arthritis in First Nations Workshop.  $25,000 (October 2012)

 

_      Canadian Institutes of Health Research.  “Early identification of rheumatoid arthritis in first nations” $960,000 (2008-2013)

 

_      Canadian Institutes of Health Research.  “Early Identification of rheumatoid arthritis in first nations” $1,117,092 (2013-2018)

 

_      Scientific Director Research Program Supplement, Canadian Institutes of Health Research.  $750,000 (2013-2018)

 

RESEARCH GRANTS AND PROTOCOLS

 

Co-investigator

_      Canadian Arthritis Society. "Lymphocyte receptors for extracellular matrix. Monoclonal antibody production". Dr J Wilkins, PI.  $52,200/yr $156,600(1991-1994).

 

_      Canadian Arthritis Society. "Cellular interactions in the rheumatoid synovium". Dr J Wilkins, PI. $62,943/yr $188,829 (1993-1996).

 

_      Children's Hospital Research Foundation. "Adhesion of lymphocytes to synovial endothelium". Dr K Oen, PI. $12,000 (1994-1995).

 

_      Disease management program in rheumatoid arthritis. Synectics Health Corporation.

 

_      Department of Radiology research fund HSC "MRI assessment of the effects of radiation synovectomy on the synovial membrane". Dr G Bock, PI. $6,000 (1994).

 

_      Canadian Arthritis Society. “Synovial lymphocyte/endothelial interactions: Identification of interactive species using monoclonal antibodies and synthetic combinatorial phage antibody display libraries” J Wilkins, PI. $60,000/yr $180,000 (1996-1999)

 

_      National Institutes of Health.  “Randomized, double blind, active treatment controlled trial of the anti TNF-_ antibody infliximab in patients with early rheumatoid arthritis”. NIH protocol 00-AR-0220, Goldbach-Mansky R, (PI, 2001-present)

 

_      Health Sciences Centre Foundation.  “Differences and determinants of the outcome of rheumatoid arthritis in Caucasian and First Nations people”.  C. Peschken, PI $30,000 (2000-2002)

 

_      Manitoba Medical Services Foundation.  “Differences and determinants of the outcome of rheumatoid arthritis in Caucasian and First Nations people”. C. Peschken, PI $10,000 (2000-2001)

 

_      Children’s Hospital Research Foundation.  “Immunogenetics and cytokine genes in rheumatoid arthritis in an aboriginal population”.  K. Oen, PI $45,000 (2000-2001)

 

_      Children’s Hospital Research Foundation.  “Immunogenetics and cytokine genes in rheumatoid arthritis in an aboriginal population”.  K. Oen, PI  $21,750/yr $43,500 (2001-2003)

 

_      Networks of Centres of Excellence (NCE).  “Osteoclastic Resorption of Inflammatory Arthritis:  Regulation of Osteoclasts and Angiogenesis b the Alpha-v Beta-3 Blockers Vitaxin”.  J. Dixon, PI  $83,000 (2002-2003)

 

_      Manitoba Medical Services Foundation. “Prognostic indicators in early synovitis” C. Hitchon, PI $40,000  (2003-2004)

 

_      Canadian Arthritis Network. “Cellular interactions in the synovium: Molecular and Functional Analyses”.  J. Wilkins, PI $71,100/yr $142,200  (2003-2005)

 

_      Networks of Centres of Excellence (NCE).  “Cellular interactions in the synovium:  Molecular and Functional Analyses”.  J. Wilkins, PI $77,100 (2003-2005)

 

_      Health Sciences Centre Foundation. “The role of the Fc-alpha receptor in arthritis” Janice Richman-Eisenstat PI $29,360 (2004-2005)

 

_      Canada Foundation for Innovation. “Program in Systems Biology” $3.5 million Co-investigators Drs. John Wilkins, Peter Nickerson, Peter Cattini, James Davie, Ronald Beavis, Werner Ens, Elissavet Kardami, Geoffery Hicks, Kevin Coombs (2004-2005)

 

_      Canadian Institutes of Health Research. “Bioengineered blood clots to promote cartilage regeneration” $140,685/yr $422,055 Dr. Caroline Hoemann (PI) (2005-2008)

 

_      Networks of Centres of Excellence (NCE) CAN-IMHA National Research Partnership in Inflammatory Joint Disease “Role of leukocytes and chitosan scaffolds in the revascularization and repair of osteochondral lesions” $99,000.  Dr. Caroline Hoemann (PI) (2006-2007)

 

_      Canadian Institutes of Health Research (CIHR).  “Bioengineered blood clots to promote cartilage regeneration” C. Hoemann, PI $422,655 (2006-2008)

 

_      Canadian Institutes of Health Research.  “Comparing rheumatoid arthritis and inflammatory bowel disease by serology, gene studies, and ethnicity:  Using commonalities and differences to develop etiologic hypotheses.  $1,305,160 Dr. Charles Bernstein (PI) (09-2007 to 08-2010)

 

_      Canadian Institutes of Health Research (CIHR).  “Defining therapeutic inflammation for articular cartilage regeneration”  C. Hoemann, PI  $136,000/yr (2008-2013)

 

INDUSTRY SPONSORED CLINICAL PROTOCOLS

 

_      A double-blind, randomized trial of Ultram TPS and Ibuprofen in OA. El-Gabalawy HS S, site PI, Ortho-McNeil (1994-1995)

 

_      An evaluation of the analgesic efficacy equivalence of Ultram and Ibuprofen in subjects with chronic pain of OA. El-Gabalawy HS, site PI, (1994-1995)

 

_      A double-blind, randomized trial of Arthrotec vs acetaminophen vs placebo. El-Gabalawy HS, site PI, Searle Canada (1995-1996)

 

_      A randomized, blinded, crossover phase II study of WinRho SD therapy of ITP secondary to SLE. WS013:  single site, El-Gabalawy HS, PI, Cangene (1995-1996)

 

_      A Canadian multicenter, randomized, double-blind placebo-controlled study of methotrexate and folic acid in SLE. SMILE El-Gabalawy HS, site PI, (1996-1998)

 

_      A double-blind, randomized, placebo controlled study to evaluate the safety and efficacy of Ro32-3555 (TROCADE) as adjunct to background anti-rheumatoid therapy, in preventing structural damage in RA. El-Gabalawy HS, Roche (1998-2000)

 

_      A comparison of the analgesic efficacy of Tramadol HCI/acetaminophen (Tramadol/APAP) versus placebo for the treatment of chronic lower back pain. El-Gabalawy HS, site PI Janssen-Ortho (1999-2000)

 

_      A phase II multi-centre, double-blind, placebo-controlled study to compare the efficacy and safety of subcutaneous 50 mg, 100 mg, 200 mg and 400 mg CDP870 vs. placebo administered at 0, 4, and 8 weeks with assessments to week 12 in the treatment of the signs and symptoms of patients with RA and a further open 36 weeks of dosing with sc 200 mg CDP870 4-weekly with assessments to week 60. El-Gabalawy HS, PI, Pharmacia (2000-2003)

 

_      A prospective multi-centre, randomized, double blind, active comparator controlled, parallel-groups study comparing the fully human monoclonal anti-TNFa antibody D2E7 given every 2nd week with methotrexate administered over 2 yrs in patients with RA (Premier). DE013. El-Gabalawy HS, PI effective March 2003, Abbott (2000-2003)

 

_      A prospective multi-centre, randomized, double-blind, active comparator controlled, parallel-group study comparing the fully human monoclonal anti-TNFa antibody D2E7 given every 2nd week with methotrexate given weekly and the combination of D2E7 and methotrexate administered over 2 yrs in pts with early RA. (Premier) DE032. El-Gabalawy HS, PI effective March 2003, Abbott (2000-2003)

 

_      A randomized, double-dummy controlled, parallel group study of the efficacy and safety of MabThera (rituximab) alone or in combination with either cyclophosphamide or methotrexate in patients with RA. El-Gabalawy HS, PI effective March 2002, Roche (2001-2002)

 

_      A phase I, Two Part, randomized, double-blind, placebo-controlled, dose escalation study to evaluate safety and pharmacokinetics of a single dose and multiple doses of MEDI-522, an av33 integrin blocker, administered intravenously to patients with active RA. MI-CP077.  El-Gabalawy HS, PI. MedImmune Inc. (2001-2003)

 

_      A randomized double blind, trial of anti-TNF chimeric monoclonal antibody (Infliximab) in combination with methotrexate compared with methotrexate alone for the treatment of patients with early rheumatoid arthritis. El-Gabalawy HS, PI. Centocor (2001-2003)

 

_      A phase IIB randomized, double blind, placebo-controlled study of the effect of H5G1. 1-MAB on RA patients with active disease despite receiving methotrexate or leflunomide.  El-Gabalawy HS, PI. Alexion (2002-2003)

 

_      A phase I, Two Part, randomized, double-blind, placebo-controlled, dose escalation study to evaluate safety and pharmacokinetics of a single dose and multiple doses of MEDI-522, an avb3 integrin blocker, administered subcutaneously to patients with active RA. MI-CP083.    El-Gabalawy HS, PI. MedImmune Inc. (2002-2004)

 

_      A multicenter international observational study of the long-term safety of Infliximab (Remicade); Results: Remicade Safety Under Long-Term Study.  El-Gabalawy HS, PI. Centocor (2002-2007)

 

 

_      A randomized, double blind, active-comparator controlled, parallel-group study to evaluate the safety of etoricoxib in patients with osteoarthritis or rheumatoid arthritis.  El-Gabalawy HS, PI.  Merck (2003-2006)

 

_      A phase III, multi-centre, randomized, double-blind, placebo-controlled clinical use study to evaluate the safety and tolerability of BMS 188667 administered intravenously to subjects with active rheumatoid arthritis with or without medical co-morbidities receiving disease modifying antirheumatic drugs (DMARDs) and/or biologics approved for rheumatoid arthritis.  El-Gabalawy HS, PI.  Bristol-Meyers Squibb (2003-2004)

 

_      A randomized, placebo-controlled, double-blind, multi-centre, parallel group, dose-ranging study to assess the safety and efficacy of multiple doses of HMR 3480 in subjects with rheumatoid arthritis on a satable dose of methotrexate. El-Gabalawy HS, PI. Aventis (2003-2004)

 

_      A study of the pharmacodynamic effects of prednisolone on whole blood protein and gene expression in rheumatoid arthritis patients. El-Gabalawy HS, PI. GlaxoSmithKline (2003-2005)

 

_      A randomized, multifactorial, double-blind, parallel-group, dose-ranging study of the efficacy and safety of rituximab (Mabthera/Rituxan) in combination with methotrexate in patients with active rheumatoid arthritis. El-Gabalawy HS, PI. Hoffman-LaRoche (2003-2004)

 

_      A phase II, randomized, double-blind safety to evaluate the effects of MEDI-522, a humanized monoclonal antibody to integrin avb3 on disease activity and progression of joint damage in patients with active rheumatoid arthritis suboptimally responding to methotrexate.  MI-CP100 El-Gabalawy HS, PI. MedImmune (2003-2004)

 

_      A randomized, double-blind, placebo-controlled evaluation of the pharmacodynamics, pharmacokinetics and safety of peat-dose T0906487 in rheumatoid arthritis subjects.  El-Gabalawy HS, PI.  Tulerik.  (2004)

 

_      A randomized, double-blind, placebo-controlled dose-ranging study to evaluate the safety and efficacy of oral TAK-715 in the treatment of the signs and symptoms of rheumatoid arthritis.  El-Gabalawy HS, PI.  Takeda (2004-2005)

 

_      A phase I dose escalation study of intra-articular administration of tgAAC94, a recombinant adeno-associated Vector containing the TNFR:Fc fusion gene, in rheumatoid arthritis.  El-Gabalawy HS, PI.  Targeted Genetics. (2004-2009)

 

_      A randomized, double-blind, double-dummy, parallel group study of the safety and efficacy of MRA monotherapy, versus methotrexate (MTX) monotherapy, in patients with active rheumatoid arthritis. El-Gabalawy HS, PI.  Roche (2005-2006)

 

_      A Phase 2a, randomized, double-blind, placebo-controlled, multicenter study to compare 3 dose levels of CP690,550 vs placebo, administered orally twice daily (BID) for 6 weeks, in the treatment of the signs and symptoms of subjects with active rheumatoid arthritis.  El-Gabalawy HS, PI Pfizer (2005-2006)

 

_      A phase III, multi-center, randomized, double-blind, placebo-controlled comparative study of Abatacept or Infliximab in combination with methotrexate in controlling disease activity in subjects with rheumatoid arthritis having an inadequate clinical response to methotrexate.  El-Gabalawy HS, PI Bristol-Myers Squibb (2005-2007)

 

_      A Randomized, placebo-controlled, double blind, multicenter, parallel-group, 12 wk study to assess the clinically effective dose range of etoricoxib and to assess its safety and tolerability in patients with RA. El-Gabalawy HS, PI .Merck (2006)

 

_      A multicenter, randomized double-blind, placebo-controlled trial of Golimumab, a fully human anti-TNFa monocolonal antibody, administered subcutaneously, in methotrexate-naēve subjects with active RA. El-Gabalawy HS, PI. Centocor (2006-2011)

 

_      RESET: Rituximab phase IIIb open-label, multi-centre, assessment of safety and effectiveness in patients with RA following inadequate response to one prior anti-TNF inhibitor.  El-Gabalawy HS, PI. Roche (2006-2008)

 

_      Treatment of DMARD naēve patients with poor prognosis rheumatoid arthritis using rituximab: A pilot study evaluating synovial outcomes.  El-Gabalawy HS, PI. Hoffman La Roche (2007-2010)

 

_      Comparison of active therapies in patient with active disease despite methotrexate therapy.  El-Gabalawy HS, PI. VA study.  (2007-2010)

 

_      A randomized, placebo controlled, multicenter clinical study investigating efficacy of rituximab (Mabthera/Rituxan) in the inhibition of joint structural damage assessed by magnetic resonance imaging in patients with rheumatoid arthritis and inadequate response to methotrexate-the SCORE study.  El-Gabalawy, PI. Hoffman-La-Roche (2007-2009)

 

_      Rheumatoid Arthritis: Comparison of Active Therapies in Patients with Active Disease Despite Methotrexate Therapy and DNA Bank Substudy.  El-Gabalawy HS, PI. The Canadian Institutes for Health Research and Department of Veterans Affairs Cooperative Studies Program, USA (2007-2010)

 

_      Digital Ischemic Lesions in Scleroderma Treated with Oral Treprostinil Diethanolamine: An open Label Multicenter extension Study. United Therapeutics Corp. Robinson D, PI.  Ethics B2009:136 PI (2009-2010)

 

_      DISTOL-1 Digital Ischemic Lesions in Scleroderma Treated with Oral Treprostinil Diethanolamine: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center study. Robinson D, PI. United Therapeutics Corp. Ethics B2009:114 (2009-2010)

 

_      A Phase I Randomized, Double-Blind, Placebo- controlled Study of the Safety and Tolerability of MEDI-551 in Scleroderma.  Robinson D, PI.   MedImmune Ethics B2010:003 (2009-2011)

 

_      A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study To Investigate The Safety, Efficacy, Pharmacokinetics and Pharmacodynamics Of 12 Weeks Of Treatment With ARRY-371797 In Patients With Active Ankylosing Spondylitis And Inadequate Response To Conventional Therapy. Hitchon C, PI. Ethics B2009:004. ARRAY (2009-2011)

 

_      A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects with Active Psoriatic Arthritis and a Psoriasis Lesion. Hitchon C, PI.  Celgene Corporation- Ethics B2010:139 (2010-2011)

 

_      A Phase 2a Randomized Double-Blinded, Placebo and Active Controlled Two Cohort Two Doses Cross-Over Multi-Center Clinical Study to Assess Efficacy of a Once Daily Administration of a Phosphodiesterase 5 Inhibitor (PF-00489791) for the Treatment of Vasospasm in Primary and Secondary Raynauds’s Phenomenon.  Robinson D, PI.   Pfizer Ethics B2010: 110 (2010-2012)

 

_      Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod In Systemic Lupus Erythematosus Patients with Active Lupus Arthritis.  Hitchon C, PI.  TEVA Pharmaceutical Industries Ltd Ethics B2010:089 (2010-2012)

 

_      A phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod Active Lupus Nephritis Patients, in Combination with Standard of Care (Mycophenolate Mofetil and Steroids.) Hitchon C, PI. TEVA Pharmaceutical Industries Ltd. Ethics B2010:055 (2010-2012)

 

RESEARCH STUDENTS SUPERVISED

 

_      Jacquie Ripat: MSc, Occupational Therapy, School of Medical Rehabilitation, University of Manitoba, 1995-1997

 

_      Raphaela Goldbach-Mansky MD: Rheumatology Research Fellowship, National Institutes of Health, Bethesda, MD; 1998-2000

 

_      Olga Zuizina BSc Med:  University of Manitoba, 2001

 

_      Kumar Dasuri PhD: Post-doctoral Fellowship, University of Manitoba, 2002-2005

 

_      Tracey Weiler PhD: Post-doctoral Fellowship, University of Manitoba, 2004-2005

 

_      Wafa Kammouni PhD: Post-doctoral Fellowship, University of Manitoba, 2005-2007

 

_      Kristin Creek BSc: Master’s Immunology, University of Manitoba, 2005-2006 (entered Medical School 2007)

 

_      Annemiek Willemze: Dutch exchange medical student, 2007.

 

_      Saurabh Mehta: MSc, Physical Therapy, School of Medical Rehabilitation, 2007-2008

 

_      Gabriela Montes Aldana:  Undergraduate student research, University of Manitoba, 2008-2009

 

_      Anne Sutherland: Medical student summer research, 2010

 

_      Janet Yuen: Undergraduate student research, 2011

 

_      Konstantin Jilkine: Medical student summer research, 2011

 

_      Thomas Winter: Summer studentship, 2012

 

_      Hester Koppejan:  Exchange MSc student (Leiden), 2013

 

_      Stefan Edginton:  Bsc med, 2013-2014

 

_      Ceri Richards:  Int Med Resident research project, 2014-2015

 

_      Nandu Anaparti:  Post-doctoral fellow, 2015

 

BIBLIOGRAPHY

 

ORIGINAL PEER REVIEWED RESEARCH PUBLICATIONS

 

1.     Jothi S., El-Gabalawy HS. Decreased population of Leu-7+natural killer cells in lymph nodes of homosexual men with AIDS-related persistent lymphadenopathy. CANADIAN MEDICAL ASSOCIATION JOURNAL, 132:47; 1985.

 

2.     El-Gabalawy HS, Keillor J.  An immunohistologic study of TCR gd chain expression in rheumatoid synovial membranes. SEMINARS IN ARTHRITIS AND RHEUMATISM. 21:239; 1992.

 

3.     Canvin J, El-Gabalawy HS, Chalmers I.  Fatal agranulocytosis with sulfasalazine. JOURNAL OF RHEUMATOLOGY 20:909-910, 1993.

 

 

 

4.     Wilkins J, Lyttle D, Sivananthan K, El-Gabalawy HS.  Lymphocyte-synovial cell interactions: A role for b1 and b3 integrin mediated adhesion to cellular fibronectin. CELLULAR IMMUNOLOGY 146:313-323, 1993.

 

5.     El-Gabalawy HS, Wilkins J.  b1 (CD29) integrin expression in rheumatoid synovial membranes. An immunohistologic study of distribution patterns. JOURNAL OF RHEUMATOLOGY. 20:231-237; 1993.

 

6.     El-Gabalawy HS, Gallatin M, Vazeau R, Peterman G, Wilkins J.  Expression of ICAM-R (ICAM-3), A novel counter-receptor for LFA-1, in Rheumatoid and non-inflammatory synovial tissues: comparison with other adhesion molecules.  ARTHRITIS AND RHEUMATISM 37:846-854, 1994.

 

7.     Bernstein CN, Pettigrew NM, El-Gabalawy HS, Sargeant MV, Meu y, Wilkins J.  Differential expression of a novel intestinal epithelial glycoprotein in various forms of inflammatory bowel disease.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 106:42-51, 1996.

 

8.     El-Gabalawy HS, Canvin JMG, Gouping M, Van der Vieren M, Hoffman P, Gallatin M, Wilkins J.  Synovial distribution of ad/CD18, a novel leukointegrin: comparison with other integrins and their ligands.   ARTHRITIS AND RHEUMATISM 39:11:1913-1921, 1996.

 

9.     El Gabalawy HS, King R, Bernstein CN, Ma G, Mou Y, Alguacil Garcia A, Fritzler M, Wilkins J.  Expression of an n-acetyl-d-galactosamine associated epitope in synovium: a potential marker of glycoprotein production.   JOURNAL OF RHEUMATOLOGY 24:1355-1363, 1997.

 

10.   Peschken C, Walker S, El-Gabalawy HS, Dancia A.  Digital necrosis as a paraneoplastic syndrome.  JOURNAL OF CLINICAL RHEUMATOLOGY 3:339-342, 1997.

 

11.   El-Gabalawy HS. Video analysis of cytokine and cell adhesion molecule staining.  JOURNAL OF RHEUMATOLOGY, 25:1860-1861, 1998.

 

12.   Oen K, El-Gabalawy HS, Canvin JMG, Hitchon C, Chalmers IM, Schroeder ML, Jacobson K, Reed M, Wood S, Cheang M.  HLA associations of seropositive rheumatoid arthritis in a Cree and Ojibway population.  JOURNAL OF RHEUMATOLOGY, 25:2319-23, 1998.

 

13.   Fang Q, Sun Y, El-Gabalawy HS, Cai W, Ko L, Chin H, Arayssi T, Schumacher HR, Williams WV.  Synovial T cell receptor heterogeneity in early arthritis.   PATHOBIOLOGY, 67:59-74, 1999.

 

14.   El-Gabalawy HS, Goldbach-Mansky R, Smith D, Arayssi T, Bale S, Gulko P, Yarboro C, Wilder RL, Klippel JH, Schumacher Jr HR.  Association of HLA alleles and clinical features in patients with synovitis of recent onset.  ARTHRITIS AND RHEUMATISM, 42:8:696-1705, 1999.

 

15.   Sen M, Lauterbach K, El-Gabalawy HS, Firestein GS, Corr M, Carson DA. Expression and function of wingless and frizzled homologs in rheumatoid arthritis. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, 97:6:2791-2796, 2000.

 

16.   Goldbach-Mansky R, Lee JM, Hoxworth JM, Smith II D, Duray P, Schumacher Jr. HR, Yarboro CH, Klippel JH, Kleiner D, El-Gabalawy HS. Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis.  ARTHRITIS RESEARCH 2:2:145-153, 2000.

 

17.   Frucht DM, Aringer M, Galon G, Danning CL, Akrad M, Brown M, Centola M, Chang-You Wu, Yamada N, Cheng T, Fan S, Steiner G, El-Gabalawy HS. O’Shea JJ. Stat4 is expressed in activated peripheral blood monocytes, dendritic cells, and macrophages at sites of Th-1 mediated inflammation.   JOURNAL OF IMMUNOLOGY, 164:4659-4664, 2000.

 

18.   Gérard HC, Schumacher Jr. HR, El-Gabalawy HS, Goldbach-Mansky R, Hudson AP.  Chlamydia pneumoniae infecting the human synovium are viable and metabolically active.  MICROBIAL PATHOGENESIS 29:17-24, 2000.

 

19.   Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS, Steiner S, Rosen A, Zhang C, Ménard HA, Zhou ZJ, Palosuo T, Van Venrooij W, Wilder RL, Klippel JH, Schumacher Jr HR, El-Gabalawy HS.  Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset.   ARTHRITIS RESEARCH, 2:3:236-243, 2000.

 

20.   Nanki T, Hayashida K, El-Gabalawy HS, Suson S, Shi K, Girschick HJ, Yavuz S, Lipsky PE. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4(+) T cell accumulation in rheumatoid arthritis synovium. JOURNAL OF IMMUNOLOGY, 165:6590-6598, 2000

 

21.   El-Gabalawy HS, Duray P, Goldbach-Mansky R.  Evaluating patients with arthritis of recent onset: studies in pathogenesis and prognosis.   JAMA. 284:2368-2373, 2000

 

22.   Gerber L, El-Gabalawy HS, Arayssi T, Furst G, Yarboro C, Schumacher Jr HR.  Polyarticular arthritis, independent of rheumatoid factor, is associated with poor functional outcome in recent onset inflammatory synovitis. JOURNAL OF BACK AND MUSCULOSKELETAL REHABILITATION, 14:105-109:2000.

 

23.   Brennan MT, Pillemer SR, Goldbach-Mansky R, El-Gabalawy HS, Schumacher H JR, Fox PC. Focal sialadenitis in patients with early synovitis. CLINICAL EXPERIMENTAL RHEUMATOLOGY, 19(4):444-6: 2001.

 

24.   Gerard HC, Wang Z, Wang GF, El-Gabalawy HS, Goldbach-Mansky R, Li Y, Majeed W, Zhang H, Ngai N, Hudson AP, Schumacher HR. Chromosomal DNA from a variety of bacterial species is present in synovial tissue from patients with various forms of arthritis. ARTHRITIS AND RHEUMATISM 44(7):1689-97: 2001.

 

25.   Hitchon CA, Danning CL, Illei GG, El-Gabalawy HS, Boumpas D.  Gelatinase expression and activity in the synovium and skin of patients with erosive psoriatic arthritis.  JOURNAL OF RHEUMATOLOGY, 29(1):107-117: 2002.

 

26.   Gerard HC, Wang Z, Whittum-Hudson JA, El-Gabalawy HS, Goldbach-Mansky R, Bardin T, Schumacher HR, Hudson AP.  Cytokine and Chemokine mRNA Produced in Synovial Tissue Chronically Infected with Chlamydia trachomatis and C. pneumoniae. JOURNAL OF RHEUMATOLOGY 29:1827-1835, 2002.

 

27.   Hitchon CA, Wong K, Guoping M, Reed J, Lyttle D, El-Gabalawy HS.  Hypoxia induced production of stromal cell-derived Factor-1 (CXCL-12) and vascular endothelial growth factor of synovial fibroblasts.  ARTHRITIS AND RHEUMATISM 46:10:2587-2597:2002.

 

28.   Canvin JMG, Bernatsky S, Hitchon CA, Jackson M, Sowa MG, Mansfield JR, Eysel HH, Mantsch HH, El-Gabalawy HS. Infrared spectroscopy: Shedding light on synovitis in patients with rheumatoid arthritis.   RHEUMATOLOGY 42:76-82: 2003.

 

29.   Newkirk MM, Goldbach-Mansky R, Lee J, Hoxworth J, McCoy A, Yarboro C, Klippel J, El-Gabalawy HS.  Advanced glycation end-product (AGE)-damaged IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis.  ARTHRITIS RESEARCH AND THERAPY 5:2:R82-R90, 2003.

 

30.   Groh V, Bruhl A, El-Gabalawy HS, Nelson L, Spies T.   Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis.  PROC NATL ACAD SCI USA, 100:9452-7, 2003.

 

31.   Gerber LH, Furst G, Yarboro C, El-Gabalawy HS. Number of active joints, not diagnosed, is the primary determinant of function and performance in early synovitis. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 21:5, Suppl. 31:65-70 2003.

 

32.   Matsumoto I, Lee D, Goldbach-Mansky R, Sumida T, Hitchon C, Schur P, Anderson R, Coblyn J, Weinblatt M, Brenner M, Duclos B, Pasquali JL, El-Gabalawy HS, Mathis D, Benoist C. Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders.  ARTHRITIS AND RHEUMATISM 48:4:944-954, 2003.

 

33.   Dasuri K, Antonovici M, Chen K, Wong K, Standing K, Ens W, El Gabalawy HS, Wilkins J. The Synovial Proteome: Analysis of Fibroblast-like Synoviocytes.   ARTHRITIS RESEARCH & THERAPY 6:2:R161-168, 2004.

 

34.   Hitchon C, Alex P, Erdile L, Frank M, Dozmorov I, Tang Y, Wong K, Centola M, El-Gabalawy HS.  A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis.  JOURNAL OF RHEUMATOLOGY 31:2336-2346, 2004.

 

 

 

35.   HLA 2004: Immunobiology of the Human MHC. Proceedings of the 13th International Histocompatibility Workshop and Congress.  (Hansen JA and Dupont B, eds), Volume I & II, IHWG Press, Seattle, WA, 2004.   ISBN: 0-945278-03

 

36.   Goldbach-Mansky R, Suson S, Wesley R, Hack E, El-Gabalawy HS, Tak PP.  Raised granzyme B levels are associated with erosions in patients with early rheumatoid factor positive rheumatoid arthritis.   ANNALS OF RHEUMATIC DISEASE, 64:5:715-721, 2005.

 

37.   Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin PR, Petri M, Edworthy S, Barr S, Gordon C, Bae SC, Sibley J, Isenberg D, Rhaman A, Aranow C, Dooley A, Steinsson K, Nived O, Sturfelt G, Alarcon G, Senecal JL, Zummer M, Hanly J, Ensworth S, Pope J, El-Gabalawy HS, McCarthy T, St. Pierre Y, Ramsey-Goldman R, and Clarke A.  An International Cohort Study of Cancer in Systemic Lupus Erythematosus.  ARTHRITIS AND RHEUMATISM 52:1481-1490, 2005.

 

38.   Oen K, Robinson DB, Nickerson P, Katz SJ, Cheang M, Peschken CA, Canvin JMG, Hitchon CA, Schroeder ML, El-Gabalawy HS.  Familial seropositive rheumatoid arthritis in North American Native Families:  Effects of shared epitope and cytokine genotypes.  JOURNAL OF RHEUMATOLOGY 32:983-991, 2005.

 

39.   Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin PR, Gordon C, Barr S, Edworthy S,  Bae SC, Petri M, Sibley J, Isenberg D, Rhaman A, Steinsson K Aranow C, Dooley MA, Alarcon GS, Hanly J,Sturfelt G.,  Nived O, Pope J, Ensworth S, Rajan R., El-Gabalawy HS, McCarthy T, St. Pierre Y, Clarke A, and Ramsey-Goldman R.  Race/ethnicity and cancer occurrence in systemic lupus erythematosus.  ARTHRITIS AND RHEUMATISM 53:781-784, 2005.

 

40.   Newkirk MM, Goldbach-Mansky R, Senior BW, Klippel J, Schumacher HR Jr, El-Gabalawy HS. Elevated levels of IgM and IgA antibodies to Proteus mirabilis and IgM antibodies to Escherichia coli are associated with early rheumatoid factor (RF)-positive rheumatoid arthritis. RHEUMATOLOGY (Oxford), 44:1433-1441, 2005.

 

41.   Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, Urowitz M, Fortin PR, Petri M, Barr S, Gordon C, Bae SC, Isenberg D, Zoma A, Aranow C, Dooley MA, Nived O, Sturfelt G, Steinsson K, Alarcon G, Senecal JL, Zummer M, Hanly J, Ensworth S, Pope J, Edworthy S, Rahman A, Sibley J, El-Gabalawy H, McCarthy T, St. Pierre Y, Clarke A and Ramsey-Goldman.  Mortality in System Lupus Erythematosus.  ARTHRITIS AND RHEUMATISM 54:2250-2557, 2006.

 

42.   Schumacher HR, Paul C, Hitchon CA, El-Gabalawy HS, Zonay L, Clayburne G, Sieck M, Schwab E.  Hyaluronate effects on synovium and synovial fluid.  A prospective blinded study in patients with osteoarthritis of the knee.  OSTEOARTHRITIS AND CARTILAGE 14:501-503, 2006

 

 

 

43.   Keeling SO, Landewe R, van der Heijde D, Bathon J, Boers M, Garnero P, Geusens P, El-Gabalawy H, Inman RD, Kraus VB, Kvien TK, Mease PJ, Ostergaard M, Ritchlin C, Syversen SW, Maksymowych WP.  Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials:  the example of C-reactive protein.  JOURNAL OF RHEUMATOLOGY 34:623-633, 2007

 

44.   Maksymowych WP, Landewe R, Boers M, Garnero P, Geusens P.  El-Gabalawy H, Heinegard D, Krause V, Lohmander S, Matyas J, Saxne T, van der Heijde D.  Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials.  JOURNAL OF  RHEUMATOLOGY 34:634-640, 2007

 

45.   Weiler T, Du Q, Krohkin O, Ens W, Standing K, El-Gabalawy H, Wilkins JA.  The identification and characterization of a novel protein c19orf10 in synovium. ARTHRITIS RESEARCH & THERAPY  9:A60626P, 2007

 

46.   Kammouni W, Wong K, Ma G, Firestein GS, Gibson SB, El-Gabalawy HS. Regulation of apoptosis in fibroblast-like synoviocytes by the hypoxia-induced Bcl-2 family member Bcl-2/adenovirus E1B 19-kd protein-interacting protein 3. ARTHRITIS AND RHEUMATISM 56: 2854-63, 2007

 

47.   Alex P, Szodoray P, Knowlton N, Dozmorov IM, Turner M, Frank MB, Arthur RE, Willis L, Flinn D, Hynd RF, Carson C, Kumar A, El-Gabalawy HS, Centola M.  Multiplex serum cytokine monitoring as a prognostic tool in rheumatoid arthritis. CLIN EXP RHEUMATOL 25:584-92, 2007

 

48.   Harris ML, Darrah E, Lam GK, Bartlett SJ, Giles JT, Grant AV, Gao P, Scott WW Jr, El-Gabalawy H, Casciola-Rosen L, Barnes KC, Bathon JM, Rosen A. Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis.  ARTHRITIS AND RHEUMATISM 58:1958-67, 2008

 

49.   Ioan-Facsinay A., Willemze A., Robinson D., Peschken C., Markland J., Van der Woude D., Elias B., Menard HA., Newkirk M., Fritzler M., Toes REM., Huizinga TWJ., El-Gabalawy HS. “Marked differences in fine-specificity and isotype usage of the anti-citrullinated peptide response in health and disease.” ARTHRITIS AND RHEUMATISM 59:3000-8, 2008

 

50.   Willemze A., Ioan-Facsinay A., El-Gabalawy H. “Evolution of Anti-Citrullinated protein antibody (ACPA) response is associated with synovial immune deposits in a patient with suspected early rheumatoid arthritis.” JOURNAL OF RHEUMATOLOGY 35:2282-4, 2008

 

51.   Fortin PR, Abrahamowich M, Ferland D, Lacaille D, Smith CD, Zummer M; Canadian Network for Improved Outcomes in Systemic Lupus Erythematosus (CaNIOS). “Steroid-Sparing Effects Of Methotrexate In Systemic Lupus Erythematosus: A Double-Blind, Randomized, Placebo-Controlled Trial.” ARTHRITIS AND RHEUMATISM 59:1796-804, 2008

 

52.   Dwivedi RC, Dhindsa N, Krokhin OV, Cortens J, Wilkins JA, El-Gabalawy HS. The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients. ARTHRITIS RESEARCH AND THERAPY. 11:R32, 2009 

 

53.   Simard P, Galarneau H, Marois S, Rusu D, Hoemann CD, Poubelle PE, El-Gabalawy HS, Fernandes MJ. Neutrophils exhibit distinct phenotypes toward chitosans with different degrees of deacetylation: implications for cartilage repair. ARTHRITIS RESEARCH AND THERAPY 11:R74, 2009

 

54.   El-Gabalawy HS, Robinson D., Hart D., Elias B., Markland J., Peschken C., Schroeder M., Fritzler JJ., Cheang M., Oen K. “Immunogenetic risks of anti-cyclical citrullinated (CCP) antibodies in North American Native patients with RA and their first degree relatives.” JOURNAL OF RHEUMATOLOGY 36:1130-1135, 2009

 

55.   Hoemann CD, El-Gabalawy HS, McKee MD. In vitro osteogenesis assays: Influence of the primary cell source on alkaline phosphatase activity and mineralization. PATHOLGIE BIOLOGIE  57:318-23, 2009

 

56.   Hitchon CA, El-Gabalawy HS, Bezabeh T. Characterization of Synovial Tissue from Arthritis Patients: A Proton Magnetic Resonance Spectroscopic Investigation. RHEUMATOLOGY INTERNATIONAL 29:1205-11, 2009

 

57.   Bresnihan B, Pontifex E, Thurlings RM, Vinkenoog M, El-Gabalawy HS, Fearon U, Fitzgerald O, Gerlag DM, Rooney T, van de Sande MG, Veale D, Vos K, Tak PP. Synovial Tissue Sublining CD68 Expression Is a Biomarker of Therapeutic Response in Rheumatoid Arthritis Clinical Trials: Consistency Across Centers. JOURNAL OF RHEUMATOLOGY. 36:1800-2, 2009

 

58.   Maksymowych WP, Fitzgerald O, Wells GA, Gladman DD, Landewé R, Ostergaard M, Taylor WJ, Christensen R, Tak PP, Boers M, Syversen SW, Bathon JM, Ritchlin CJ, Mease PJ, Bykerk VP, Garnero P, Geusens P, El-Gabalawy HS, Aletaha D, Inman RD, Kraus VB, Kvien TK, van der Heijde D. Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design. JOURNAL OF RHEUMATOLOGY 36:1792-9, 2009

 

59.   Maksymowych WP, Landewé R, Tak PP, Ritchlin CJ, Ostergaard M, Mease PJ, El-Gabalawy HS, Garnero P, Gladman DD, Fitzgerald O, Aletaha D, Bykerk VP, Bathon  JM, Syversen SW, Boers M, Geusens P, Inman RD, Kraus VB, Kvien TK, Taylor WJ, Wells GA, van der Heijde D. Reappraisal of OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis: The OMERACT 9 v2 Criteria. JOURNAL RHEUMATOLOGY 36:1785-91, 2009

 

 

 

60.   Syversen SW, Landewe R, van der Heijde D, Bathon JM, Boers M, Bykerk VP, Fitzgerald O, Gladman DD, Garnero P, Geusens P, El-Gabalawy HS, Inman RD, Kraus V, Kvien TK, Mease PJ, Ostergaard M, Ritchlin CJ, Tak PP, Taylor WJ, Maksymowych WP.  Testing of the OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage in Rheumatoid Arthritis: A Systematic Literature Search on 5 Candidate Biomarkers. JOURNAL OF RHEUMATOLOGY 36:1769-84, 2009

 

61.   Mease PJ, Hobbs K, Chalmers A, El-Gabalawy HS, Bookman A, Keystone E, Furst DE, Anklesaria P, Heald AE. Local delivery of a recombinant adeno-associated vector containing a tumor necrosis factor-{alpha} antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study. ANNALS OF RHEUMATIC DISEASES 68:1247-54, 2009

 

62.   Guzman-Morales J., El-Gabalawy HS, Pham M.H., Tran-Khanh N., McKee M.D., Wu W., Centola M., and Hoemann CD. “Effect of chitosan particles and dexamethasone on human bone marrow stromal cell osteogenesis and angiogenic factor secretion.  BONE 45(4):617-26, 2009

 

63.   Haraoui B, El-Gabalawy H, Khraishi M, Thorne C. Is the Canadian healthcare system neglecting a significant proportion of the rheumatoid arthritis population? JOURNAL OF RHEUMATOLOGY 36(12):2841, 2009

 

64.   Hitchon CA, Chandad F, Ferucci ED, Willemze A, Ioan-Facsinay A, van der Woude D, Markland J, Robinson DB, Elias B, Newkirk M, Toes R, Huizinga T, El-Gabalawy HS “Antibodies to Porphyromonas Gingivalis are Associated with Anti-Citrullinated Protein Antibodies in RA Patients and their Relatives” JOURNAL OF RHEUMATOLOGY, 37:1105-12, 2010

 

65.   Hoemann C, Chen G., Marchand C., Tran-Khanh N, Chevrier A., Thibault M., Sun J., Shive M., Fernandes M., Poubelle P., Centola M., and El-Gabalawy H. “Scaffold-guided subchondral bone repair:  implication of neutrophils and alternatively activated arginase-1+macrophases”.  AMERICAN JOURNAL OF SPORTS MEDICINE 38:1845-56, 2010

 

66.   Peschken C, Hitchon CA,  Robinson D, Smolik I, Prematilake S, Barnabe C, El-Gabalawy HS. “Rheumatoid Arthritis in a North American Native Population: Longitudinal Follow-up and Comparison with a Caucasian Population.” JOURNAL OF RHEUMATOLOGY 37:1589-95, 2010

 

67.   Bernstein CN, El-Gabalawy HS, Sargent M, Landers CJ, Rawsthorne P, Elias B, Targan SR. “Assessing inflammatory bowel disease-associated antibodies in Caucasian and First Nations cohorts” CANADIAN JOURNAL OF GASTROENTEROLOGY 25:269-273, 2011

 

68.   Turner-Brannen E, Choi KY, Arsenault R, El-Gabalawy HS, Napper S, Mookherjee N. “Inflammatory cytokines IL-32 and IL-17 have common signalling intermediates despite differential dependence on TNF-R1”, JOURNAL OF IMMUNOLOGY 86:7127-35, 2011

 

69.   El-Gabalawy HS, Robinson DB, Daha NA, Oen KG, Smolik I, Elias B Hart D, Bernstein CN, Sun Y, Lu Y, Houwing-Duistermaat JJ, Siminovitch KA.”Non-HLA Genes Modulate the Risk of Rheumatoid Arthritis Associated with HLA-DRB1 in a Susceptible North American Native Population” GENES AND IMMUNITY, 12:568-74, 2011

 

70.   Turner-Brannen E, Choi KY, Lippert DN, Cortens JP, Hancock RE, El-Gabalawy H, Mookherjee N. Modulation of interleukin-1_-induced inflammatory responses by a synthetic cationic innate defence regulator peptide, IDR-1002, in synovial fibroblasts. ARTHRITIS RESEARCH AND THERAPY, 13:R129, 2011

 

71.   La D, Czarnecki C, El-Gabalawy HS, Kumar A, Meyers A, Bastien N, J. Simonsen N, Plummer FA, Luo M: “Enrichment of Variations in KIR3DL1/S1 and KIR2DL2/L3 among H1N1/09 ICU Patients: an Exploratory Study”. PLoS ONE, 6(12), 2011

 

72.   Mehta S, Shay B, A.Szturmm A, El-Gabalawy HS. “Kinematic Analysis of Gait following Intra-articular Corticosteroid Injection into the Knee Joint with an Acute Exacerbation of Arthritis” PHYSIOTHERAPY CANADA, 63(4);395-404, 2011

 

73.   Saeed M, Rubinger M, Ahsanuddin A, Morales C, Penner B, Robinson D, El-Gabalawy H, Zarychanski R. “If at first you don't succeed: Try, try again.”  AMERICAN JOURNAL OF HEMATOLOGY 87(3):295-7, 2012

 

74.   Blanchard A, Wang X, El-Gabalawy HS, Tan Q, Orr P, Elias B, Rawsthorne P, Hart D, Chubey S, Bernstein CN. “Oral health in a First Nations and a non-Aboriginal population in Manitoba”, JOURNAL OF CIRCUMPOLAR MEDICINE, 71:17394, 2012

 

75.   Newkirk MM, Mitchell S, Procino M, Li Z , Cosio M, Mazur W, Kinnula VL, Fritzler M, El-Gabalawy HS: “Chronic smoke exposure induces rheumatoid factor and anti-heat shock protein 70 autoantibodies in susceptible mice and humans with lung disease” EUROPEAN JOURNAL OF IMMUNOLOGY, 42(4):1051-61, 2012

 

76.   Suwannalai P, van de Stadt LA, Radner H, Steiner G, El-Gabalawy HS, van Schaardenburg D, Huizinga TWJ, Toes REM, Trouw LA: Avidity maturation of ACPA in rheumatoid arthritis, ARTHRITIS AND RHEUMATISM, 64(5):1323-8, 2012

 

77.   Murdoch TB, Bernstein CN, El-Gabalawy HS,  Stempak JM, Sargent M,  Elias B,  Xu W, Pathan S, Silverberg MS: “Prevalence of genetic variants associated with inflammatory bowel disease in a healthy First Nations cohort”, CANADIAN MEDICAL ASSOCIATION JOURNAL,  184(8):E435-4, 2012

 

78.   El-Gabalawy HS, Robinson DB, Smolik I, Hart D, Elias B, Wong SK, Peschken CA, Hitchon CA, Li X, Bernstein CN, Newkirk MM, Fritzler MJ: “Familial clustering of the serum cytokine profile in the relatives of rheumatoid arthritis patients” ARTHRITIS AND RHEUMATISM 64(6):1720-9, 2012

 

79.   Allen D, Fischer A, Bshouty Z, Robinson D, Peschken C, Hitchon C, El-Gabalawy H, Meyers M, Mittoo S. “Evaluating systemic lupus erythematosus patients for lung involvement”. LUPUS.  21(12):1316-25, 2012      

 

80.   Hitchon CA, Sun Y, Robinson DB, Peschken CA, Bernstein CN, Siminovitch KA, El-Gabalawy HS. “Vitamin D receptor polymorphism rs2228570 (Fok1) is associated with rheumatoid arthritis in North American natives”. JOURNAL OF RHEUMATOLOGY. 39(9):1792-7, 2012

 

81.   Peschken CA, Robinson DB, Hitchon CA, Smolik I, Hart D, Bernstein CN, El-Gabalawy HS. “Pregnancy and the Risk of Rheumatoid Arthritis in a Highly Predisposed North American Native Population”. JOURNAL OF RHEUMATOLOGY 39(12):2253-60, 2012

 

82.   Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin JF, Petri M, Zoma A, Manzi S, Urowitz MB, Gladman D, Fortin PR, Ginzler E, Yelin E, Bae SC, Wallace DJ, Edworthy S, Jacobsen S, Gordon C, Dooley MA, Peschken CA, Hanly JG, Alarcón GS, Nived O, Ruiz-Irastorza G, Isenberg D, Rahman A, Witte T, Aranow C, Kamen DL, Steinsson K, Askanase A, Barr S, Criswell LA, Sturfelt G, Patel NM, Senécal JL, Zummer M, Pope JE, Ensworth S, El-Gabalawy H, McCarthy T, Dreyer L, Sibley J, St Pierre Y, Clarke AE. “Cancer risk in systemic lupus: An updated international multi-centre cohort study”.  JOURNAL OF AUTOIMMUNOLOGY S0896-8411(13)00011-5, 2013

 

83.   Smolik I., Robinson D., Bernstein C., El-Gabalawy H.  The First-Degree Relatives of Rheumatoid Arthritis Patients Exhibit a High Prevalence of Joint Symptoms”, JOURNAL OF RHEUMATOLOGY 40(6):818-24, 2013

 

84.   O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, Lew RA, Cannella AC, Kunkel G, Phibbs CS, Anis AH, Leatherman S, Keystone E; CSP 551 RACAT Investigators. Therapies for active rheumatoid arthritis after methotrexate failure. NEW ENGLAND JOURNAL OF MEDICINE  369(4):307-18, 2013

 

85.   Heard BJ, Fritzler MJ, Wiley JP, McAllister J, Martin L, El-Gabalawy H, Hart DA, Frank CB, Krawetz R.  “Intraarticular and Systemic Inflammatory Profiles May Identify Patients with Osteoarthritis”  JOURNAL OF RHEUMATOLOGY  40(8):1379-87, 2013

 

86.   Ferucci ED, Darrah E, Smolik I, Choromanski TL, Robinson DB, Newkirk MM, Fritzler MJ, Rosen A, El-Gabalawy HS: “Prevalence of Anti-Peptidylarginine Deiminase Type 4 Antibodies in Rheumatoid Arthritis and Unaffected First-Degree Relatives in Indigenous North American Populations” JOURNAL OF RHEUMATOLOGY 40(9):1523-8, 2013 

 

87.   Mookherjee N, El-Gabalawy HS. “High degree of correlation between whole blood and PBMC expression levels of miR-155 and miR-146a in healthy controls and rheumatoid arthritis patients”. JOURNAL OF IMMUNOLOGY METHODS 400-401:106-10, 2013

 

88.   Amir Shaghaghi M, Bernstein CN, Serrano León A, El-Gabalawy H, Eck P. “Polymorphisms in the sodium-dependent ascorbate transporter gene SLC23A1 are associated with susceptibility to Crohn disease”.  AMERICAN JOURNAL OF CLINICAL NUTRITION. 99(2):378-83, 2014

 

89.   Deane KD, El-Gabalawy H.  “Pathogenesis and prevention of rheumatic disease:  focus on preclinical RA and SLE”.  NATURE REVIEWS RHEUMATOLOGY 10(4):212-28, 2014

 

90.   Serrano León A1, Amir Shaghaghi M, Yurkova N, Bernstein CN, El-Gabalawy H, Eck P.  “Single-nucleotide polymorphisms in SLC22A23 are associated with ulcerative colitis in a Canadian white cohort.”  AMERICAN JOURNAL OF CLINICAL NUTRITION. 100(1):289-94, 2014

 

91.   Heard BJ, Rosvold JM, Fritzler MJ, El-Gabalawy H, Wiley JP, Krawetz RJ  “A computational method to differentiate normal individuals, osteoarthritis and rheumatoid arthritis patients using serum biomarkers”  JOURNAL OF THE ROYAL SOCIETY INTERFACE  6;11(97), 2014

 

92.   Al-Zoobi L, Salti S, Colavecchio A, Jundi M, Nadiri A, Hassan GS, El-Gabalawy H, Mourad W.  “Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface”  INTERNATIONAL IMMUNOLOGY 26(8):451-65, 2014

 

93.   Passmore SR, El-Gabalawy H, French S.  “The Launch of the Institute of Musculoskeletal Health and Arthritis 2014-2018 Strategic Plan: Positive Implications for Canadian Chiropractors and their Patients.”  JOURNAL OF THE CANADIAN CHIROPRACTIC ASSOCIATION  58(4):337-41, 2014

 

94.   O'Neil L, Robinson D, Hamza S, El-Gabalawy H. “Protracted superficial granulomatosis with polyangiitis: a therapeutic challenge”.  JOURNAL OF CLINICAL RHEUMATOLOGY  21(1):49-51, 2015

 

95.   Dwivedi RC, Krokhin OV, El-Gabalawy HS, Wilkins JA.  “Development of a Selected Reaction Monitoring (SRM) method for absolute quantitation of MYDGF/C19orf10 protein”.  PROTEOMICS - CLINICAL APPLICATIONS  2015  Epub ahead of print

 

96.   Koppejan H, Trouw L, Sokolove J, Lahey LJ, Huizinga T.J.W., Smolik I, Robinson DR, El-Gabalawy HS, Toes REM, Hitchon CA. “Anti-Carbamylated Protein Antibodies in Indigenous North Americans with Rheumatoid Arthritis, their First-Degree Relatives and Controls: Comparison to Anti-Citrullinated Protein Antibodies.”  In press JOURNAL OF RHEUMATOLOGY

 

97.   Edginton S, Hitchon CA, Froese W, El-Gabalawy HS. “Effects of rituximab and infliximab treatment on carboxypeptidase B and its substrates in RA synovium” In press JOURNAL OF RHEUMATOLOGY

 

98.   Meng X, Ezzati P, Smolik I, Hitchon CA, El-Gabalawy HS.  “Characterization of Endogenous Autoantigens Bound to Anti Citrullinated Protein Antibodies in Rheumatoid Arthritis: A Key Role for Citrulline Residues in Histone 4”.  Submitted

 

 

 

PEER REVIEWED EDITORIALS AND REVIEWS

 

1.     El-Gabalawy HS. The many faces of lupus. CANADIAN FAMILY PHYSICIAN, 36:983; 1990

 

2.     Canvin JMG, El-Gabalawy HS.  Anti-inflammatory therapy.  RHEUMATIC DISEASE CLINICS IN REHABILITATION AND PHYSICAL MEDICINE, 10:301-317, 1999

 

3.     El-Gabalawy HS. The challenge of early synovitis: multiple pathways to a common clinical syndrome.   ARTHRITIS RESEARCH, 1:31-36, 1999

 

4.     Hitchon CA, El-Gabalawy HS.  Immune features of seronegative and seropositive arthritis in early synovitis studies.  CURRENT OPINION IN RHEUMATOLOGY, 14:4:348-353, July 2002

 

5.     El-Gabalawy HS, Lipsky PE.  Why do we not have a cure for rheumatoid arthritis?  ARTHRITIS RESEARCH, 4:(suppl. 3), S297-301, 2002

 

6.     Hitchon C, El-Gabalawy HS. Histopathology of early synovitis. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 21:5 Suppl.31, S28-36, 2003

 

7.     El-Gabalawy HS, Wilkins JA.  Anti-Sa Antibodies:  Prognostic and pathogenetic significance to rheumatoid arthritis.  ARTHRITIS RESEARCH AND THERAPY 6:86-89, 2004

 

8.     Hitchon C, El-Gabalawy HS. Oxidation in Rheumatoid Arthritis.  ARTHRITIS RESEARCH AND THERAPY 6:265-278, 2004

 

9.     Singh R, Robinson D, El-Gabalawy HS.  Emerging biologic therapies in rheumatoid arthritis:  cell targets and cytokines.   CURRENT OPINION IN RHEUMATOLOGY 17:274-279, 2005

 

10.   El-Gabalawy H. Common denominators of inflammatory joint diseases.  JOURNAL OF RHEUMATOLOGY Suppl Jan: 72:3-6, 2005

 

11.   Hitchon CA, Peschken, CA, Shaikh S, El-Gabalawy H.  Early Undifferentiated Arthritis.

      RHEUMATIC DISEASE CLINICS OF NORTH AMERICA   31:605-626, 2005

 

12.   McCulloch CA, Downey GP and El-Gabalawy H. Signalling platforms that modulate the inflammatory response: new targets for drug development.   NATURE REVIEW DRUG DISCOVERY 5:864-76 OCT 2006

 

13.   Brar A, Hiebert T, El-Gabalawy H.  Should patients with RA with a history of malignancy receive anti-TNF therapy? Still no clear answer.  NATURE CLINICAL PRACTICE RHEUMATOLOGY. 3:120-121 2007

 

 

 

14.   El-Gabalawy H, Ryner L.  Central nervous system abnormalities in fibromyalgia: assessment using proton magnetic resonance spectroscopy. JOURNAL OF RHEUMATOLOGY 35:1242-4, 2008

 

15.   El-Gabalawy HS. “The preclinical stages of RA: lessons from human studies and animal models”.  BEST PRACTICE & RESEARCH RHEUMATOLOGY 23:49-58, 2009

 

16.   Smolik I, Robinson D and El-Gabalawy HS.  “Periodonitis and Rheumatoid Arthritis:  Epidemiologic, Clinical, and Immunologic Associations”.  COMPENDIUM OF CONTINUING EDUCATION IN DENTISTRY 30:188-197, 2009

 

17.   Inman RD, El-Gabalawy HS.  “The immunology of AS and RA:  a tale of similarities and dissimilarities.”  CLINICAL AND EXPERIMENTAL RHEUMATOLOGY (4 Suppl 55):S26-32, 2009

 

18.   Rahman P, Inman RD, El-Gabalawy HS, Krause D.  “Pathophysiology & Pathogenesis of Immune-mediated Inflammatory Diseases: Commonalities and Differences”.  JOURNAL OF RHEUMATOLOGY, 37:S85, 2010

 

19.   El-Gabalawy HS, Guenther L, Bernstein CN.  “Epidemiology of IMIDs: Incidence Prevalence, Natural History and Comorbidities”.  JOURNAL OF RHEUMATOLOGY, 37:S85, 2010

 

20.   Mookherjee N, El-Gabalawy H. Defining the mechanism of action of herbal therapies in rheumatoid arthritis: is this the road to clinical development and acceptance? JOURNAL OF RHEUMATOLOGY 38:1817-9, 2011

 

21.   Hitchon CA, El-Gabalawy HS. Infection and rheumatoid arthritis: still an open question. CURRENT OPINION IN RHEUMATOLOGY 23:352-7, 2011

 

22.   Lotrich FE, El-Gabalawy HS, Guenther LC, Ware CF: “The role of inflammation in the pathophysiology of depression: Different treatments and their effects” JOURNAL OF RHEUMATOLOGY Suppl. 38:48-54, 2011

 

23.   Rosenbaum JT, Russell AS, Guenther LC, El-Gabalawy H: The influence of uveitis on patients with immune-mediated inflammatory disease. JOURNAL OF RHEUMATOLOGY Suppl. 38:26-30, 2011

 

24.   Hitchon CA, El-Gabalawy HS “The synovium in rheumatoid arthritis” Open Rheumatology Journal 5:107-14, 2011

 

BOOK CHAPTERS

 

1.     El-Gabalawy HS Rheumatology in COMPUCONSULTS, Mayer Zev Enterprises Ltd. 1997.

 

2.     Hitchon C, El-Gabalawy HS. An approach to diffuse musculoskeletal pain. CANADIAN JOURNAL OF CONTINUING MEDICAL EDUCATION. 9:95-106, 1997.

 

3.     Canvin JMG, El-Gabalawy HS. Antiinflammatory therapy. RHEUMATIC DISEASE CLINICS IN REHABILITATION AND PHYSICAL MEDICINE, 10:301-317, 1999.

 

4.     El-Gabalawy HS, Lipsky PE. The Spondyloarthropathies. SAMTER’S IMMUNOLOGIC DISEASES TEXTBOOK, Lippincott Williams & Wilkins, Austen KF, Frank MM, Atkinson JP, Cantor H, 6th Edition, Vol II: CH 43:PP 531-546, 2001.

 

5.     El-Gabalawy HS, Lipsky PE. Immune Mechanisms. IN MECHANISMS IN RHEUMATOLOGY TEXTBOOK.  Core Health Services Inc., Tannenbaum H, Russell A, Editors, CH 3:PP 17-28, 2001.

 

6.     El-Gabalawy HS “Evaluation of the Patient: History and Physical Examination”. PRIMER IN THE RHEUMATIC DISEASES, Arthritis Foundation, Ed. Klippel JH 12th Edition, CH 7: PP 117-124, 2001.

 

7.     El-Gabalawy HS, Lipsky PE “Reactive Arthritis: Etiology and Pathogenesis”. RHEUMATOLOGY, 3rd Edition, Vol 2: CH 108:PP1225-1232, 2003.

 

8.     Robinson D, El-Gabalawy HS “Evaluation of the Patient: History and Physical Examination”. PRIMER IN THE RHEUMATIC DISEASES, Arthritis Foundation, Ed. Klippel JH 13th Edition, CH 2: PP 6-14, 2008.

 

9.     El-Gabalawy, HS: Chapter 48: Synovial Fluid Analyses, Synovial Biopsy, and Synovial Pathology.  KELLEY’S TEXTBOOK OF RHEUMATOLOGY, 8th Edition, 2008

 

10.  El-Gabalawy, HS: Chapter 48: Synovial Fluid Analyses, Synovial Biopsy, and Synovial Pathology.  KELLEY’S TEXTBOOK OF RHEUMATOLOGY, 9th Edition, 2012

 

PUBLISHED ABSTRACTS

 

1.              El-Gabalawy HS, Henderson J. "The prognostic value of serum levels of sIL2R in RA" ARTHRITIS AND RHEUMATISM, 34:S156, 1991.

 

2.              El-Gabalawy HS, Wilkins J. "An immunohistologic study of VLA antigen expression in rheumatoid synovial tissues" ARTHRITIS AND RHEUMATISM, 34:S169, 1991.

 

3.              El-Gabalawy HS, Stupack D, Wilkins J. "Adhesion molecule expression in rheumatoid synovial cells" CLINICAL AND INVESTIGATIVE MEDICINE. 14:B74, 1992.

 

4.              El-Gabalawy HS, Wilkins J. "b1 integrin expression on rheumatoid synovium" JOURNAL OF RHEUMATOLOGY 32:38, 1992.

 

5.              El-Gabalawy HS, Gallatin M, Peterman G, Wilkins J. "Expression of ICAM-R, A novel counter-receptor for LFA-1, in rheumatoid synovial tissues".  ARTHRITIS AND RHEUMATISM 36:S246, 1993

 

6.              El-Gabalawy HS, Alguacil-Garcia A, Wilkins J. "Synovial expression of a novel 110 kd adhesion related molecule".  ARTHRITIS AND RHEUMATISM 36:S245, 1993.

 

7.              Minenko A, Bergal P, El-Gabalawy HS. "Inpatient rehabilitation of rheumatoid patients” ARTHRITIS AND RHEUMATISM 36:S98, 1993.

 

8.              El-Gabalawy HS, Alguacil-Garcia A, Wilkins J. "Expression of a novel 110 kDa protein in synovial tissues" CLINICAL AND INVESTIGATIVE MEDICINE 1994.

 

9.              El-Gabalawy HS: ICAM-2 is not constitutively expressed by all synovial endothelium.  ARTHRITIS AND RHEUMATISM 183;S189, 1994.

 

10.           Bernstein CN, Pettigrew NM, Weinstein WM, El-Gabalawy HS, Sargeant MV, Wilkins J. "The goblet cell expression of a novel peptide recognized by A13D8 in various forms of colitis".  GASTROENTEROLOGY 108:A781, 1995.

 

11.           El-Gabalawy HS, Oen K, Wilkins J. "Co-expression of macrophage and fibroblast markers by RA synovial lining cells in culture and in situ” ARTHRITIS AND RHEUMATISM 38:S156, 1995.

 

12.           Bock GW, Davidson MJ, Larrigan J, Hart D, El-Gabalawy HS. Evaluation of p32 radiosynovectomy in chronic knee synovitis with gadolinium enhanced magnetic resonance imaging" ARTHRITIS AND RHEUMATISM 38:S242, 1995.

 

13.           El-Gabalawy HS, Canvin JMG, Ma M, Hoffman P, Gallatin M, Wilkins J. "Synovial distribution of ad/b2, a novel leukointegrin: comparison with other integrins and their ligands." presented at the annual meeting of the Canadian Rheumatology Association, Lake Louise, Alberta, Feb. 1996

 

14.           Hitchon C, Canvin JMG, El-Gabalawy HS. "Comparison of natives and caucasians with rheumatoid arthritis at presentation to rheumatology clinic" presented at the annual meeting of the Canadian Rheumatology Association, Lake Louise, Alberta, Feb. 1996

 

15.           Chalmers IM, Baragar FD, El-Gabalawy HS. "A case control study of natives and caucasians with rheumatoid arthritis" presented at the annual meeting of the Canadian Rheumatology Association, Lake Louise, Alberta, Feb. 1996

 

16.           El-Gabalawy HS, Canvin JMG, Ma M, Hoffman P, Gallatin M, Wilkins J. "Synovial distribution of ad/b2, a novel leukointegrin: comparison with other integrins and their ligands." ARTHRITIS AND RHEUMATISM 39:S34, 1996

 

17.           El Gabalawy HS, King R, Bernstein CN, Ma G, Mou Y, Alguacil Garcia A, Fritzler M, Wilkins J. “Monoclonal antibody A13D8 identifies a 110 KD glycoprotein in synovium: a potential indicator of mucin production” ARTHRITIS AND RHEUMATISM 39:S34, 1996

 

18.           El-Gabalawy HS, Ma M, Oen K, Wilkins J “Are cultured synoviocytes derived from the synovial lining cell layer?” ARTHRITIS AND RHEUMATISM 39:S34, 1996.

 

19.           Canvin J, El-Gabalawy HS. “Outcome evaluations for a rheumatology day hospital program”. JOURNAL OF RHEUMATOLOGY. 24:1435, 1997

 

20.           Bernatsky S, Canvin J, El-Gabalawy HS. “Effects of the acute phase response on hematological parameters in rheumatoid arthritis”. JOURNAL OF RHEUMATOLOGY 24:1435, 1997

 

21.           Bernatsky S, Canvin J, El-Gabalawy HS. “Interpretation of positive cultures in arthrocentesis”. JOURNAL OF RHEUMATOLOGY 24:1435, 1997

 

22.           Canvin J, Hitchon CA, El-Gabalawy HS. “Rheumatoid arthritis presents ten years earlier in Algonkian north American Indians”. ARTHRITIS AND RHEUMATISM 40:S, 1997

 

23.           Peschken C, El-Gabalawy HS, Esdaile J. “Predicting remissions in rheumatoid arthritis”. ARTHRITIS AND RHEUMATISM 40:S 1997

 

24.           Oen K, El-Gabalawy HS, Canvin JMG. “Age-specific HLA associations of seropositive rheumatoid arthritis in a Canadian Native population”.  ARTHRITIS AND RHEUMATISM 41:Suppl 1998

 

25.           Goldbach-Mansky R, Schumacher HR, Bale S, Klippel J, Wilder R, Arayssi T, Yarboro C, El-Gabalawy HS. “Immunogenetic associations in patients with early synovitis” ARTHRITIS AND RHEUMATISM 41:S. 1998

 

26.           Hitchon CA, Cheang M, Wardell J, El-Gabalawy HS, Canvin JMG “Alternative therapy use in rheumatoid arthritis: Prevalence and patient characteristics” ARTHRITIS AND RHEUMATISM 41:S 1998

 

27.           Peschken CA, El-Gabalawy HS, Roos LL, Esdaile JM. “The prevalence of rheumatoid arthritis: Administrative data with clinical dataset validation” ARTHRITIS AND RHEUMATISM 41:S 1998

 

28.           Goldbach-Mansky R, Hudson A, Gerard H, Wang G, Smith D, Arayssi T, Yarboro C, Wilder R, Klippel J, El-Gabalawy HS, Schumacher HR “Does the presence of C-trachomatis in synovial tissue correlate with immune serology and outcome in recent onset synovitis?” ARTHRITIS AND RHEUMATISM 41:S 1998

 

29.           Goldbach-Mansky R, Schumacher HR, Smith D, Aryassi T, Yarboro C, Wilder R, Klippel J, El-Gabalawy HS. “Relationship between infectious symptoms, immune serology to arthritogenic pathogens, and 1 year outcome in patients with synovitis of recent onset.” ARTHRITIS AND RHEUMATISM 41:S 1998

 

30.           Illei G, Schumacher HR, Arayssi T, Yarboro C, Smith D, Klippel J, El-Gabalawy HS. “Patterns of antirheumatic drug therapy in patients with early arthritis.” ARTHRITIS AND RHEUMATISM 41:S 1998

 

31.           Illei G, Schumacher HR, Goldbach-Mansky R, Klippel J, Wilder R, Smith D, Gerber L, Arayssi T, Yarboro C, El-Gabalawy HS. “Predictors of remission in patients with early synovitis” ARTHRITIS AND RHEUMATISM 41:S 1998

 

32.           Goldbach-Mansky R, Schumacher HR, Klippel J, Wilder R, Aringer M, Arayssi T, Yarboro C, El-Gabalawy HS, “Lack of concordance between criteria based diagnoses and clinical diagnoses in a cohort of patients with synovitis” ARTHRITIS AND RHEUMATISM 41: S 1998

 

33.           Canvin JMG, Bernatsky S, Jackson M, Sowa M, Mansfield J, El-Gabalawy HS. “Differentiating early from late rheumatoid synovitis by infrared spectroscopy” ARTHRITIS AND RHEUMATISM 41: S 1998

 

34.           Peschken CA, El-Gabalawy HS, Roos LL, Esdaile JM. “Algonkian Indians have twice the frequency of rheumatoid arthritis with a younger age of onset” ARTHRITIS AND RHEUMATISM 41: S 1998

 

35.           Hitchon CA, Danning CL, Illei GG, Lee J, El-Gabalawy HS, Boumpas DT. “Matrix metalloproteinase expression and activity in psoriatic arthritis skin and synovium” ARTHRITIS AND RHEUMATISM 42:S 1999.

 

36.           Sen M, El-Gabalawy HS, Firestein GS, Carson DA, Corr M.  “Potential role of the wingless and frizzled embryonic growth factors in rheumatoid synovial hyperplasia”. ARTHRITIS AND RHEUMATISM 42:S 1999.

 

37.           Goldbach-Mansky R, Lee JM, Hitchon C, Danning C, Hoxworth J, Schumacher Jr HR, Wilder RL, El-Gabalawy HS.  “Synovial gelatinase expression and activity are associated with radiographic erosions in patients with early synovitis” ARTHRITIS AND RHEUMATISM 42: S 1999

 

38.           Canvin J, Chalmers I, El-Gabalawy HS. “Utility of outcome measures in decisions to change DMARD therapy for rheumatoid arthritis” ARTHRITIS AND RHEUMATISM 42: S 1999

 

39.           Lee JM, Hoxworth J, Goldbach-Mansky R, Deville C, Yarboro C, Smolen J, Steiner G, Klippel JH, Wilder RL, El-Gabalawy HS. “Serum levels of angiogenic growth factors in patients with early synovitis” ARTHRITIS AND RHEUMATISM 42: S 1999

 

40.           Goldbach-Mansky R, Hoxworth J, Lee JM, Smolen J, Steiner G, Menard H, Griffiths MM, Palosuo T, Yarboro C, Klippel JH, Wilder RL, El-Gabalawy HS. “RA associated autoantibodies define subsets of patients with early synovitis” ARTHRITIS AND RHEUMATISM 42: S 1999

 

41.           Goldbach-Mansky R, McCoy A, Lee JM, Newkirk M, El-Gabalawy HS. “Advanced glycation end product (AGE) IgG and autoantibodies to AGE-IgG in patients with early synovitis” ARTHRITIS AND RHEUMATISM 42: S 1999

 

42.           Hitchon C, Bezebeh T, Canvin J, El-Gabalawy HS. “Supplementation of rheumatoid and osteoarthritis patients with antioxidant vitamins does not result in a detectable clinical, histologic, or biochemical response in the synovial membrane.” ARTHRITIS AND RHEUMATISM 42: S 1999

 

43.           Brennan MT, Pillemer SR, Goldbach-Mansky R, Kleiner D, El-Gabalawy HS, Wilder RL, Schumacher Jr. HR, Klippel JH, Fox PC. “Focal sialadenitis in patients with early synovitis” ARTHRITIS AND RHEUMATISM 42: S 1999

 

44.           Hoxworth J, Goldbach-Mansky R, Lee JM, Deville C, Smolen J, Steiner G, Menard H, Griffiths MM, Palosuo T, Yarboro C, Klippel JH, Wilder RL, El-Gabalawy HS. “Predictors of early radiographic erosions in patients with synovitis of recent onset” ARTHRITIS AND RHEUMATISM 42: S 1999

 

45.           Bezabeh T, Hitchon C, Canvin J, Marwaha J, Smith ICP, El-Gabalawy H.  “1H MRS of synovial tissue: correlating the degree of inflammation with spectral features in rheumatoid arthritis patients.  Proceedings of the International Society of Magnetic Resonance in Medicine.  P 1524.  1999.

 

46.           Gerard HC, Wang Z, Wang GF, Li Y, Majeed W, El-Gabalawy H, Goldbach-Mansky R., Ngai N, Hudson AP, Schumacher RH Jr., Detroid MI. “Chromosomal DNA from a variety of bacterial species is present in synovial tissue in patients with various forms of arthritis.” ARTHRITIS AND RHEUMATISM 43:S 2000

 

47.           Goldbach-Mansky R, Suson S, Hoxworth J, Hack CE, Peters KMC, El-Gabalawy HS, Tak PP. “Elevated serum granzyme B levels are associated with erosions in patients with early rheumatoid arthritis” ARTHRITIS AND RHEUMATISM 43: S 2000

 

48.           Carpten JC, Suson S, Robbins C, Goldbach-Mansky R, Trent J, El-Gabalawy HS. “CACP gene mutations mediating a familial synovial hyperplasia syndrome do not account for synovial hyperplasia in RA” ARTHRITIS AND RHEUMATISM 43: S 2000

 

49.           Goldbach-Mansky R, Suson S, Duray P, Hoxworth J, Wilder RL, Schumacher Jr HR, El-Gabalawy HS. “The histopathologic spectrum of early synovitis” ARTHRITIS AND RHEUMATISM 43: S 2000

 

50.           Goldbach-Mansky R, Senior B, Suson S, Deville C, Hoxworth J, Newkirk M, Klippel JH, Schumacher Jr HR, El-Gabalawy HS. “IgM AND IgA antibodies to proteus mirabilis are associated with early RF positive RA” ARTHRITIS AND RHEUMATISM 43: S 2000

 

 

 

51.           Suson S, Goldbach-Mansky R, Schneider E, Schumacher Jr HR, Duray P, Koch A, El-Gabalawy HS. “Characteristics of synovial microvasculature in patients with synovitis of recent onset” ARTHRITIS AND RHEUMATISM 43: S 2000

 

52.           Hoxworth JM, Goldbach-Mansky R, Yarboro CH, Klippel JH1, Wilder RL, Schumacher Jr HR, El-Gabalawy HS. “Interaction between DQ and DR loci in susceptibility to seropositive RA”. ARTHRITIS AND RHEUMATISM 43: S 2000

 

53.           Reed J, Goldbach-Mansky R, Lee J, Suson S, Kucukcetin B, Brown K, Young N, Wilder RL, Schumacher Jr HR, Koenig S, El-Gabalawy HS. “parvovirus B19 in the synovium of patients with early synovitis” ARTHRITIS AND RHEUMATISM 43: S 2000

 

54.           Gerber L, Furst G, Goldbach-Mansky R, Schneider E, Hoxworth JM, El-Gabalawy HS “Early indicators of poor function in arthritis”. ARTHRITIS AND RHEUMATISM 43: S 2000

 

55.           Bezabeh T, Hitchon C, Canvin J, Patel R, El-Gabalawy H. 1H MR spectral features correlate with measures of tissue vascularity in the synovial joints of rheumatoid arthritis patients.  Proceedings of the Internal Society of Magnetic Resonance in Medicine.  P. 1084. 2001

 

56.           El-Gabalawy HS, Peschken CA, Roos LL, Esdaile JM.  “Declining incidence of rheumatoid arthritis may be primarily in the elderly”. JOURNAL OF RHEUMATOLOGY 28: S 2001

 

57.           Hitchon CA, Canvin JMG, Chalmers IM, Peschken CA, Robinson DB, El-Gabalawy HS. “Rheumatoid arthritis in Canadian Algonkian Indians: Earlier onset but comparable outcome”. JOURNAL OF RHEUMATOLOGY 28: S 2001

 

58.           Goldbach-Mansky R, Matsumoto I, Benoist C, Mathis D, El-Gabalawy HS. “Prevalence of reactivity to glucose-6-phosphate isomerase (GPI) in patients with synovitis of recent onset”.  ARTHRITIS AND RHEUMATISM 44: S 2001

 

59.           Hitchon CA, Ziouzina O, Wong K, Lyttle D, Reed JL, El-Gabalawy HS.  “Hypoxic induction of rheumatoid synovial VEGF expression mediated by HIF-1_: A potential mechanism for synovial angiogenesis”. ARTHRITIS AND RHEUMATISM 44: S 2001

 

60.           Sen Malini, Reifert J, El-Gabalawy H, Carson D.   “WNT1 Signaling from rheumatoid arthritis synoviocytes”. ARTHRITIS AND RHEUMATISM 44: S 2001

 

61.           Canvin JM, Hitchon CA, El-Gabalawy HS.  “Rheumatoid arthritis day hospital education program provides patients with sustained benefit and control”. ARTHRITIS AND RHEUMATISM 44: S 2001

 

 

 

62.           Shaikh SA, Goldbach-Mansky R, El-Gabalawy HS, Peschken CA.  “Persistent undifferentiated inflammatory arthritis: Longterm outcome”. ARTHRITIS AND RHEUMATISM 44: S 2001

 

63.           Hayer S, Tohidast-Akrad K, Schett G, Skriner K, El-Gabalawy H, Isabaloglou L, Kollias G, Smolen J, Steiner G.  "Aberrant expression of the autoantigen HNRNP-A2/RA33 in the joints of patients with RA and in TNF_ transgenic mice: A clue to autoimmunity? ARTHRITIS AND RHEUMATISM 44: S 2001

 

64.           Hitchon CA, Ziouzina O, Hart D, Wong K, El-Gabalawy HS. “Are hypoxic synovial fluid conditions associated with measures of synovial angiogenesis?” ARTHRITIS AND RHEUMATISM 46:6:S548 2002

 

65.           El-Gabalawy HS, Hitchon CA, Ma G, El-Gabalawy NC, Bailey JL, White AM, Jones RE, Lyttle D, Davis LS. “Vitaxin, a humanized monoclonal antibody, inhibits alpha V/beta3 integrin in human RA synovial tissue engrafted into SCID mice”. ARTHRITIS AND RHEUMATISM 46:6:S546 2002

 

66.           El-Gabalawy HS, Lipsky PE. “Why do we not have a cure for rheumatoid arthritis?” ARTHRITIS RESEARCH, 4:(suppl. 3), S297-301 2002

 

67.           Hitchon CA, van Venrooij W, Mathis D, Matsumoto I, Benoist C, El-Gabalawy H. “Native American Indians with early rheumatoid arthritis have a higher prevalence of autoantibodies”. ARTHRITIS AND RHEUMATISM 46:6:S542 2002

 

68.           Hitchon CA, El-Gabalawy H.  “Immune features of seronegative and seropositive arthritis in early synovitis studies.” CURRENT OPINION IN RHEUMATOLOGY 14:4:S348 2002

 

69.           Nelson L, Lambert N, Brautbar C, El-Gabalawy H, Fraser P, et el. “The 13th international histocompatibility working group for rheumatoid arthritis joint report”. ARTHRITIS AND RHEUMATISM 48:9:S143 2003

 

70.           Bernatsky S, Ramsey-Goldman R., Boivin J, Joseph L, Rajan R, Zoma A, Manzi S, Urowitz M, Gladman D, Fortin P, Gordon C, Bae S, Sibley J, Edworth S, Barr G, Isenberg D, Rahman A, El-Gabalawy H, et el. “Cancer in systemic lupus erythematosus (SLE): An international mutli-centre cohort study”. ARTHRITIS AND RHEUMATISM 48:9:S696 2003

 

71.           Bernatsky S, Clarke A, Boivin F, Joseph L, Rajan R, Manzi S, Urowitz M, Gladman D, Fortin P, Gordon C, Bae S, Sibley J, Edworthy S, Barr S, Isenberg D, Rahman A, El-Gabalawy H et al. “Racial factors relating to cancer occurrence in systemic lupus (SLE)”. ARTHRITIS AND RHEUMATISM 48:9:S696 2003

 

72.           Hitchon CA, Alex P, Erdile L, Frank MB, Dozmorov I, Tang Y, Centola M, El-Gabalawy H. “A distinct multi-cytokine profile is associated with anti-CCP antibodies in patients with early untreated inflammatory arthritis”. ARTHRITIS AND RHEUMATISM 48:9:S544 2003

 

73.           Wover R, Yu J, Wong K, El-Gabalawy H, Richman-Eisenstat J. “Human fibroblast-like synoviocytes express the Fc-alpha receptor (CD89)”. ARTHRITIS AND RHEUMATISM 48:9:S474 2003

 

74.           Kumar D, Keng W, El-Gabalawy H, Wilkins J.  “Exploration of the synovial fibroblast proteome using 2D gels and MALDI-TOF-MS”. ARTHRITIS AND RHEUMATISM 48:9:S419 2003

 

75.           El-Gabalawy H, Bathon J, Yocum D, Wilder R.  “Safety and Pharmacokinetics (PK) of a single dose of MEDI-522, an antagonist of integrin Alpha V Beta 3 (_vß3), in patients with active rheumatoid arthritis (RA)”. ARTHRITIS AND RHEUMATISM 48:9:S140 2003

 

76.           El-Gabalawy H, Hitchon CA, Schumacher R Jr., Yarboro C, Duray P, Goldbach-Mansky R.  “Synovial histopathological features and RA autoantibodies predict persistence in patients with synovitis of recent onset”. ARTHRITIS AND RHEUMATISM 48:9:S667 2003

 

77.           El-Gabalawy H, Wilkins J, Dasuri K, Duggan D.  “Changes in the synovial cell proteome induced by hypoxia”.  ARTHRITIS RESEARCH THERAPY.  5:S3:S39 2003

 

78.           Hitchon CA, Wilkins J, Der S, Wilkins O, Koshigi M, Huang E, El-Gabalawy HS. Hypoxic regulation of stromal derived factor-1 (SDF-1) in rheumatoid synovitis (to be presented at the Keystone Symposia: Biology of hypoxia: The role of oxygen sensing in development, normal function and disease (D3) Mar 26 2004.

 

79.           Hitchon CA, Dasuri K, Wilkins O, Wong K, Ma Guoping, Der S, El-Gabalawy HS. “Leptin expression in patients with inflammatory arthritis: evidence for hypoxic regulation. ARTHRITIS AND RHEUMATISM 50:9:S59 2004

 

80.           El-Gabalawy HS, Hitchon CA, Dasuri K, Wong K, Ma G, Cheng K, Wilkins O, Der S, Wilkins JA. “Response of fibroblast-like synoviocytes to hypoxia is mediated by HIF-1a dependent and independent mechanisms.  ARTHRITIS AND RHEUMATISM 50:9:S12 2004.

 

81.           Hitchon CA, Wong K, Alex P, Centola M, Poole R, El-Gabalawy HS. “Elevated aggrecan and collagen turnover markers are associated with rheumatoid factor, antibodies to cyclical citrullinated peptide and cytokine profiles in early untreated inflammatory arthritis”. ARTHRITIS AND RHEUMATISM 50:9:S166 2004.

 

82.           Peschken CA, Barnabe C, Hitchon C, Robinson D, El-Gabalawy HS. “Algonkian Indians have severe rheumatoid arthritis in spite of aggressive treatment”.  ARTHRITIS AND RHEUMATISM 50:9:S556, 2004

 

83.           Kammouni W, Wong K, Guoping M, Gibson S, El-Gabalawy HS. “Expression and hypoxic regulation of the pro-apoptotic protein BNIP3 in rheumatoid synovitis.  ARTHRITIS AND RHEUMATISM 52:9:S572, 2005

 

84.           El-Gabalawy HS, Guoping M, Stroescu D, Wong K, Hitchon CA. “Gene expression profiles in patients with untreated rheumatoid synovitis:  Distinct subsets based on matrix metalloproteinase (MMP) gene expression levels”.  ARTHRITIS AND RHEUMATISM 52:9:S572, 2005

 

85.           Jacob T, Hart D, Craig A, Robinson DB, Hitchon C A, Ferland D, Elias B,  Markland JJ, Wong K, Peschken CA, Newkirk M, El-Gabalawy HS.  “IgM immune responses to Proteus Mirabilis and E Coli are associated with rheumatoid factor not RA in Native American Indians”.  ARTHRITIS AND RHEUMATISM 54:9:S197, 2006

 

86.           Jacob T, Elias B, Hitchon CA., Robinson DB, Ferland D, Craig A, Wong K, Hart D, Markland JJ, Knowlton N, Peschken CA, Centola M, El-Gabalawy HS.  Biomarker Analysis in Native American Indian RA patients and their first degree relatives.  ARTHRITIS AND RHEUMATISM 54:9:S196, 2006

 

87.           Singh R, Stroescu D, Gouping M, Wong K, El-Gabalawy HS, Hitchon CA.  Synovial MMP expression in untreated early RA patients:  Distinct subsets based on synovial MMP1 and MMP3 mRNA levels.  JOURNAL OF RHEUMATOLOGY 33(2): 101 pg 398  2006

 

88.           Hitchon CA, Craig A, Wong K, Ferland D, Hart D, Peschken CA, Robinson D, El-Gabalawy HS. “Remission in early inflammatory arthritis is predicted by absence of antibodies to cyclical citrullinated peptides”. ARTHRITIS AND RHEUMATISM 54:9:S204, 2006

 

89.           Peschken CA, Hart D, Ferland D, Wong K, Craig A, Hitchon CA, Markland DB, Menard HA, Elias B, El-Gabalawy HS. “Identification and characterization of native American Indians at high risk for developing RA”.    ARTHRITIS AND RHEUMATISM 54:9:S819, 2006

 

90.           Creek K, Mao Su-Yau, El-Gabalawy HS.  “Expression and pro-inflammatory activity of high mobility group box 1(HMGB1) in rheumatoid synovitis”.  ARTHRITIS AND RHEUMATISM 54:9:S221, 2006

 

91.           Brar A, Sargent M, Wong K, El-Gabalawy N, Bernstein C, El-Gabalawy H, Hitchon C, “Antibodies to cyclical citrullinated peptide (CCP) are associated with lower serum osteoprotegrin (OPG) in early inflammatory arthritis” JOURNAL OF RHEUMATOLOGY 33:2:C103 2006.

 

92.           Brar A, Peschken CA, Robinson DB, El-Gabalawy HS, Hitchon CA “Clinical outcome in early undifferentiated arthritis is predicted by antibodies to cyclical citrullinated peptides” JOURNAL OF RHEUMATOLOGY.  Supplement 2007.

 

93.           Dhindsa NK, Ferland DS, Craig, El-Gabalawy H, Peschken CA.  “High risk of Cardiovascular Events in First Nations Women with Combined Rheumatoid Arthritis and Diabetes.” JOURNAL OF RHEUMATOLOGY.  Supplement 2007

 

94.           Hitchon C, Brar A, Nguyen T, Wong K, Knowlton N, Centola M, El-Gabalawy H.  “Serum Cytokine Profiles Identify a Subset of Patients with Early Inflammatory Arthritis Responsive to Early DMARD Therapy.” Podium presentation at ACR Meeting 2007, Boston.

 

95.           Dwivedi RC, El-Gabalawy HS, Krohkin O, Wilkins JA, “Proteomic Analysis of Serum From RA patient Under Anti-TNF-a Therapy” ARTHRITIS AND RHEUMATISM 56:9:S243, 2007

 

96.           Hitchon CA, Nguyen T, Brar A, Wong K, Knowlton N, Centola M, El-Gabalawy HS. “Serum Cytokine Profiles Identify  a Subset of Patients with Early Inflammatory Arthritis Responsive to Early DMRAD Therapy.” ARTHRITIS AND RHEUMATISM 56:9:S832, 2007

 

97.           Rosen A, Harris M, Lam GK, Bartlett SJ, Grant AV, Gao P, El-Gabalawy H, Casciola-Rosen L, Barnes KC, Bathon JM. “Autoimmunity to the Polymorphic Region of a major Susceptibility Gene Occurs Frequently in Rheumatoid Arthritis.” ARTHRITIS AND RHEUMATISM 56:9:S318, 2007

 

98.           El-Gabalawy H, Robinson D, Hart D, Elias B, Peschken C, Schroeder M, Markland J, Nelson JL, Fritzler M, Oen K. “HLA-DRB1*0901 is Associated with Anti-CCP Antibodies in Native American RA Patients and Their First Degree Relatives.” ARTHRITIS AND RHEUMATISM 56:9:S430, 2007

 

99.           Newkirk MM, Jacob T, Robinson D, Hart D, Elias B, Peschken C, Markland J, El-Gabalawy H. “Rheumatoid Disease Process and/or Therapy Differentially Impact on IgM and IgA Rheumatoid Factor Responses in Affected Native Americans When Compared to Unaffected High Risk Relatives.” ARTHRITIS AND RHEUMATISM 56:9:S715, 2007

 

100.        Dhindsa NK, Ferland DS, Craig AR, El-Gabalawy H, Peschken CA. High risk of Cardiovascular Events in First Nations Women with Combined Rheumatoid Arthritis and Diabetes. (Canadian Rheumatology Association Meeting Feb. 2007)

 

101.        Dhindsa N, Dwivedi RC, Hitchon CA, Ma G, Wong K, Wilkins JA, El-Gabalawy HS.  “Response to Infliximab in RA:  Systems Biology Approach to Identifying Biomarkers”.  ARTHRITIS AND RHEUMATISM 58:9:S211, 2008

 

102.        Hitchon CA, Chandad F, Ferucci E, Willemze A, Ioan-Facsinay A, Robinson D, Elias D, Newkirk M, Huizinga T, El-Gabalawy HS.  “Antibodies to P. gingivalis are Associated with Anti-Citrullinated Protein Antibodies (ACPA) in RA Patients and their Relatives”.  ARTHRITIS AND RHEUMATISM 58:9:S286, 2008

 

103.        Hitchon CA, Peschken CA, Alvarez M, Robinson D, El-Gabalawy HS, Xibille-Friedmann D.  “Differences in Inflammatory Arthritis Disease Severity Among Mexican Mestizos and Native American Indians Compared to Caucasians”.  ARTHRITIS AND RHEUMATISM 58:9:S754, 2008

 

104.        Hitchon CA, Wong K, El-Gabalawy HS.  “Measurement of Baseline Serum Matrix Metalloproteinase Levels Addess Minimal Prognostic Value Over Routine Clinical Parameters in the Prediction of Radiographic Erosions in Early Inflammatory Arthritis”.  ARTHRITIS AND RHEUMATISM 58:9:S754, 2008.

 

105.        Peschken CA, Barnabe C, Robinson DB, Hitchon CA, El-Gabalawy HS.  “Severe Rheumatoid Arthritis Phenotype in Native American Indians Compared to Caucasians”.  ARTHRITIS AND RHEUMATISM 58:9:S762, 2008.

 

106.        Dickson MC, Ellis J, Cai G, Wilson AG, Bridges SL Jr, Furst DE, O’Dell RJ, El-Gabalawy HS, Tiffany C, Sidiqqi S, Bal J, Uings IJ, Binks MH.  “Corticosteroid-responsive Pharmacodynamic Transcriptional Markers:  Results From A Randomized Placebo-controlled Study of Rheumatoid Arthritis Patients Treated with Prednisone”.  ARTHRITIS AND RHEUMATISM  58:9:S774, 2008

 

107.        Hitchon CA, Peschken CA, Montiel JL, Nickerson P, Robinson DB, El-Gabalawy HS, Xibille DX. “Differences in Inflammatory Arthritis Activity Across Mexican Mestizos, Canadian Native American Indians and Canadian Caucasians: HLA Associations”. ARTHRITIS AND RHEUMATISM 60:9:S988, 2009

 

108.        El-Gabalawy HS, Daha NA, Robinson DB, Oen KG, Smolik I, Hart, Willemze A, Ghidey W, Houwing-Duistermaat JJ, Toes REM, Huizinga TWJ, Siminovitch KA. “RA Susceptibility Is Associated with An Epistatic Interaction Between Shared Epitope Alleles and MMEL1-TNFRSF14”. (Concurrent Oral Abstract Session-Genomics of Rheumatoid Arthritis) ARTHRITIS AND RHEUMATISM 60:9:S577, 2009

 

109.        Allen D, Bshouty Z, Moyen M, Robinson DB, Peschken CA, Hitchon CA, El-Gabalawy HS, Mittoo S. “Shrinking lung syndrome is associated with pleuritis” ARTHRITIS AND RHEUMATISM 62:10 S492 2010

 

110.        Smolik I, Tan Q, Wang X, Hart D, Newkirk M, Bernstein CN, Robinson DB, El-Gabalawy HS,  “Unaffected First-Degree Relatives of RA Patients Exhibit a High Prevalence of Joint Symptoms That is not Explained by the Presence of RA Autoantibodies: Studies in a Predisposed North American Native Population”. (Poster Tour) ARTHRITIS AND RHEUMATISM 62:10 S445 2010

 

111.        Deane KD, Demoruelle K, Parish M, Hilton W, Harrington L, Derber L, Kolfenbach JR, Hughes-Austin JM, Weisman MH, Mikuls TR, O'Dell JR, Keating RM, Gregersen PK,  Buckner J, Smolik I, Hart D, Bernstein CN, Robinson DB,  Norris J, Holers VM,  El-Gabalawy HS. “Variability of Anti-CCP Kit Testing in Cohorts with and without RA” ARTHRITIS AND RHEUMATISM 62:10 S457 2010

 

112.        C. Hitchon, G. Boire, A. Lloyd, M. Centola, R. Kay, H. El-Gabalawy. “Clinical Outcome in Early Undifferentiated Arthritis is Best Predicted by a Combination of Baseline Clinical Features and Serum Biomarkers” ANNALS OF RHEUMATIC DISEASE 2011;70(Suppl3):284

 

113.        El-Gabalawy HS, Jilkine K, Robinson DB, Smolik I, Hart DM, Hitchon CA, Peschken CA, Bernstein CN, Oen K, Sun Y, Siminovitch KA.Polymorphisms in the CCL2 Distal Regulatory Region Are Associated with Rheumatoid Arthritis in a North American Native Population with a High Disease Prevalence” ARTHRITIS AND RHEUMATISM 63:10: S55 2011

 

114.        El-Gabalawy HS, Robinson DB, Hart DM, Smolik I, Bernstein CN, Newkirk MM, Fritzler MJ.  “Familial Clustering of the Serum Cytokine Profile: Comparison Between the Asymptomatic First-Degree Relatives of RA Patients and Controls with No Family History of Autoimmune Disease” (Concurrent Rheumatoid Arthritis-Human Etiology and Pathogenesis I Pathogenesis of the Earliest Stages of Rheumatoid Arthritis.) ARTHRITIS AND RHEUMATISM 63:10: S300 2011

 

115.        Hitchon CA, Boire G, Centola M, Lloyd A, Kay R, El-Gabalawy HS. “Clinical Outcome in Early Undifferentiated Arthritis Is Best Predicted by a Combination of Baseline Clinical Features and Serum Biomarkers” ARTHRITIS AND RHEUMATISM 63:10: S130 2011

 

116.        Peschken CA, Robinson DB, Smolik I, Hitchon CA, Hart DM, Bernstein CN, El-Gabalawy H. “Pregnancy and the Risk of Rheumatoid Arthritis In a High Risk North American Native Population”  ARTHRITIS AND RHEUMATISM 63:10: S468 2011

 

117.        Schacter I, Robinson DB, Hart DM, Bertone M, Peschken CA, Smolik I, Hitchon CA, El-Gabalawy H. “Prevalence of periodontitis, anti-P.Gingivalis antibodies and RA autoantibodies in a community sample of North American Natives with Prevalent RA” (Concurrent Rheumatoid Arthritis-Human Etiology and Pathogenesis I Pathogenesis of the Earliest Stages of Rheumatoid Arthritis.) ARTHRITIS AND RHEUMATISM 63:10: S301 2011

 

118.        Hitchon CA, Sun Y, Robinson DB, Peschken CA, Bernstein CN, Siminovitch KA,  El-Gabalawy HS. “Vitamin D Receptor Polymorphism rs2228570 (Fokl) in North American Natives with Rheumatoid Arthritis and Their Unaffected First Degree Relatives” ARTHRITIS AND RHEUMATISM 63:10: S843 2011

 

119.        Hitchon CA, Mookherjee N, Wong K, Peschken CA, Nickerson P, El-Gabalawy HS. “Serum 25 OH Vitamin D Levels Are Low in North American Native Populations with Early Inflammatory Arthritis but Do Not Correlate with Clinical Activity or Outcome”  (Poster Tour) ARTHRITIS AND RHEUMATISM 63:10: S135 2011

 

120.        Hitchon CA, Peschken CA, Mailley T, Dooley J, Nickerson P, El-Gabalawy HS. “Environmental and Genetic Contributions to Disease Severity in North American Natives with Early Inflammatory arthritis” ARTHRITIS AND RHEUMATISM 63:10: S832 2011

 

121.        Peschken CA, Hitchon CA, Chen H, Garland A, El-Gabalawy HS, Bernstein CN, Marrie RA. “Administrative Definitions of Rheumatoid Arthritis: Rising Prevalence Regardless of Definition Used” ARTHRITIS AND RHEUMATISM  63:10: S1009 (Concurrent Epidemiology and Health Services Research III: Rheumatoid Arthritis)  2011

 

122.        El-Gabalawy HS, Ferucci E. “Risk Factors for Rheumatoid Arthritis in Predisposed Indigenous North American Populations” Keystone Symposium Santa Fe New Mexico Jan 2012.

 

123.        Hitchon CA, Mookherjee N, Wong K, Peschken CA, El-Gabalawy HS. “Serum 25 OH Vitamin D Levels are Low in Early Inflammatory Arthritis but do not Correlate with Immune Responses to Pathogens nor Clinical Activity or Outcome” (plenary presentation) Canadian Rheumatology Association Meeting March 2012

 

124.        C. Hitchon, L. Larcombe, M. Newkirk, N. Mookherjee, C. Peschken, H. El-Gabalawy “Vitamin D Receptor Polymorphisms in Early Inflammatory Arthritis are Associated with Clinical Outcomes and IgM Responses to Common Pathogens but not Baseline Disease Activity ANNALS OF RHEUMATIC DISEASE 2012;71(Suppl3):653 2012

 

125.        El-Gabalawy HS, Robinson DB, Smolik I, Hart DM, Feucci ED, Newkirk M, Fritzler MJ, Cramb C, Sokolove J, Robinson WH. “Evolution of Preclinical Autoimmunity in Individuals At Risk for Development of Rheumatoid Arthritis” (Concurrent Rheumatoid Arthritis-Human Etiology and Pathogenesis 1). ARTHRITIS AND RHEUMATISM 64;10  S722 2012

 

126.        Barnabe C, Low Horn C, Kargard M, Mintsioulis S, Leclerq S, Mosher DP, EL-Gabalawy HS, White T, Fritzler MJ. “Detection of inflammatory arthritis and musculoskeletal conditions in a First Nations Community: Results of an Onsite Screening Program”. ARTHRITIS AND RHEUMATISM 64;10  S874 2012

 

127.        Ferucci ED, Smolik I, Chormanski TL, Robinson DB, Newkirk MM, Fritzler MJ, Rosen A, Darrah E, Hani S El-Gabalawy “Prevalence of anti-peptidylarginine deiminase type 4 antibodies in rheumatoid arthritis and unaffected first-degree relatives in Indigenous North American Populations”  ARTHRITIS AND RHEUMATISM 64;10  S511 2012

 

128.        Hitchon C, Larcombe L, Mookherjee N, Peschken CA, Newkirk M, El-Gabalawy HS. “Vitamin D receptor polymorphism are associated with clinical outcomes and IgM responses to common pathogens but not baseline disease activity in early inflammatory arthritis” ARTHRITIS AND RHEUMATISM 64;10  S505 2012

 

129.        Puar R, Hitchon CA, Robinson B, El-Gabalawy H, Dhindsa N. and Peschken CA. “Not keeping up with the Times: High Mortality and Early Death Due to Disease in North American Natives with Systemic Lupus Erythematosus (SLE)”. Arthritis and Rheumatism 64 (10); suppl S816, 2012

 

130.        O’Neil LH, Robinson D, El-Gabalawy H, Dhindsa N, Peschken C.  “Interrupted and Delayed Care in First Nation Patients with Rheumatoid Arthritis:  The Best Target for Therapy?”  Journal of Rheumatology. S42 2015

 

131.        Hitchon C, Khan S, Katz A, Elias B, El-Gabalawy H, and Peschken C.  Disparities in the Treatment of Rheumatoid Arthritis in First Nations: A Population Based Study. Presented poster at the Canadian Rheumatology Association Annual Meeting, Quebec City, February 4-7, 2015

 

132.        Puar R, Hitchon C, Robinson D, Dhindsa N, El-Gabalawy H, Peschken C. High Mortality in Vulnerable Canadians with Systemic Lupus Erythematosus. Presented oral at the Canadian Rheumatology Association Annual Meeting, February 4-7, 2015, Quebec City

 

133.        van Heemst J, Scally S, Cheng Law S, van der Woude D, Hitchon C, Robinson DB, Huizinga TWJ, Reid HH, Toes REM, El-Gabalawy H, Rossjohn J, Thomas R.  “The Shared Rheumatoid Arthritis HLA-DRB1 Susceptibility Epitope Shapes the Molecular Orientation of Citrulline and the Autoreactive T Cell Receptor Repertoire”.  American College of Rheumatology, San Francisco, CA November 6-11, 2015

 

134.        Hitchon C, Khan S, Katz A, Elias B, El-Gabalawy H, Peschken C.  “Disparities in the Treatment of Rheumatoid Arthritis in First Nations: A Population Based Study, American College of Rheumatology, San Francisco, CA, November 6-11, 2015

 

135.        Richards C, Hitchon CA, Meng X, Smolik I, Robinson D and El-Gabalawy H.  Indigenous North Americans at High Risk for RA Complement C5 Level is Associated with ACPA Positivity  and C5a with Transition to  Synovitis Even After Correcting for In Vitro Complement Activation Found with Prolonged Sample Storage. American College of Rheumatology, San Francisco, CA. November 6-11, 2015

 

136.        Hitchon C, Smolik I, Meng X, Robinson D, El-Gabalawy HS.  “Serum 14-3-3eta Are Elevated in Indigenous North Americans with Rheumatoid Arthritis and May Predict Imminent Synovitis in Their at-Risk First Degree Relatives”.  2015 ACR/ARHP Annual Meeting, November 6-11, 2015

 

INVITED LECTURESHIPS AND SCHOLARLY PRESENTATIONS

 

1.              “Follicular dendritic cells in rheumatoid synovium” Annual meeting of the Society of Atlantic Rheumatologists, Halifax, July 1988

 

2.              “Soluble IL-2 receptors in RA. Longitudinal relationship to disease activity” Annual meeting of the Society of Atlantic Rheumatologists, Moncton, July 1989

 

3.              Invited Speaker, “The rheumatoid synovium. What can we learn by looking at it” University of Saskatchewan, Saskatoon, March, 1990

 

4.              Speaker, “Soluble IL-2 receptors in rheumatoid arthritis” Medical Grand Rounds, University of Manitoba, Winnipeg, March 1991

 

5.              Speaker, “Disability and duration of inpatient admission in rheumatoid arthritis” Medical Grand Rounds, Winnipeg, University of Manitoba, Oct 1992

 

6.              Invited Speaker “Adhesion molecules expression in synovium “ Annual meeting of the Society of Atlantic Rheumatologist, Halifax, June 1993

 

7.              Invited Speaker, "What's new in the treatment of rheumatoid arthritis" Annual meeting of the Royal College of Physicians and Surgeons of Canada, Toronto, Sept 1994

 

8.              Invited Speaker, “Adhesion molecules in rheumatoid arthritis” Dalhousie University,  Dec 1994

 

9.              Invited Speaker, “Longitudinal follow-up of DMARD therapy in rheumatoid arthritis” Dalhousie University, Dec 1994.

 

10.            Invited Speaker, “The role of adhesion molecules in perpetuation of rheumatoid synovitis“ Annual meeting of the Society of Atlantic Rheumatologists, , Prince Edward Island, June 1995

 

11.            Invited Speaker, “New concepts in the pathogenesis and treatment of rheumatoid arthritis “ 25th Anniversary reunion of Faculty of Medicine Alumni, University of Calgary, Calgary, AB October 1995

 

12.            Speaker, “Pathogenesis of rheumatoid arthritis “ Medical Grand Rounds, St Boniface Hospital, Winnipeg, MB Nov 1995

 

13.            “Risks of NSAIDs in the elderly” Annual meeting of the Canadian Geriatric Association, Toronto, ON 1996

 

14.            Speaker, “Oxidative stress in rheumatoid arthritis” Medical Grand Rounds. University of Manitoba, Winnipeg, MB March 1997

 

15.            Speaker, “Approach to Diffuse Musculoskeletal Pain” Rheumatology Continuing Medical Education for Family Physicians, University of Manitoba June 6, 1997

 

16.            Invited Speaker, “Studies in early synovitis” Rehabilitation and Physical Medicine Grand Rounds. University of Manitoba, Winnipeg, MB January 1998

 

17.            Invited speaker, “Redefining the role of NSAIDs in arthritis”. Faculty Development Program. Searle. Maui. January 1998

 

18.            Invited speaker, “Arthritis of recent onset: Pathogenesis, prognosis and therapy”.  “New directions in pain management” symposium, sponsored by the Arthritis Foundation, Washington DC chapter, Bethesda, MD, USA November 21, 1998

 

19.            Speaker, “Arthritis of recent onset: Studies in pathogenesis and prognosis”. NIH Clinical Center, Bench to Bedside Grand Rounds, Bethesda, MD, USA January 13, 1999

 

20.            “Arthritis of recent onset: Studies in pathogenesis and prognosis”. NIH Clinical Center, Round Table presentation, panel leader, Bethesda, MD, March 26, 1999

 

21.            “Novel therapies for managing early arthritis”. Pharmacotherapy frontiers ’99. NIH pharmacy Dept. Masur Auditorium, Bethesda, MD, USA April 17, 1999

 

22.            “Predictors of bone erosion in patients with synovitis of recent onset”. Fourth International Synovitis Workshop, Dallas, Tx, USA April 25, 1999

 

23.            “Pathogenesis, prognosis, and treatment of early synovitis”, Annual meeting of the Society of Atlantic Rheumatologists, Bar Harbor, Me, June 18, 1999

 

24.            “Generalized musculoskeletal pain”. American College of Rheumatology High Impact Rheumatology Course, NIH, Bethesda, MD, USA June 25, 1999 

 

25.            “Association of HLA alleles and clinical features in patients with synovitis of recent onset”. Workshop on HLA in Rheumatoid Arthritis, Leiden, NETHERLANDS, Sept 18, 1999

 

26.            Invited speaker, “New insights into the pathogenesis of early synovitis”, Emory University, Atlanta, USA Oct 6, 1999

 

27.            “Early Synovitis: Pathogenesis, prognosis and therapy”, Rheumatology Grand Rounds, Georgetown University, USA Dec 22, 1999

 

28.            “Synovitis of recent onset: new insights into pathogenesis and treatment”, Clinical Staff Conference, NIH Clinical Center Grand Rounds, USA Feb 23, 2000

 

29.            “The challenge of early synovitis: multiple pathways to a common clinical syndrome”. Rheumatology Grand Rounds, University of Western Ontario, May 11, 2000

 

30.            _v_3 integrin as a therapeutic target in inflammatory arthritis” Skeletal Biology Seminar, University of Western Ontario, May 12, 2000

 

31.            “Pathogenesis of bone erosions in early synovitis”, invited speaker and recipient of the Jeff Shiroky Award in Rheumatology, Laurentian Rheumatology Conference, Val David, Quebec, May 25, 2000

 

32.            “Prognosis and treatment of early arthritis”, Rehabilitation Medicine Grand Rounds, University of Manitoba, Sept 11, 2000

 

 

33.            “Pathogenesis and prognosis of early synovitis”, Immunology Seminar, University of Manitoba, Oct 13, 2000

 

34.            “Early rheumatoid arthritis”, Moderator, State of the Art Lecture, annual meeting of the American College of Rheumatology, Philadelphia, USA Nov 3, 2000

 

35.            “Pathogenesis of rheumatoid arthritis”, Chair, Plenary Session, annual meeting of the Canadian Rheumatology Association, Mont Tremblant, Quebec, Feb 22, 2001

 

36.            Speaker, “Parvovirus B19 and rheumatoid arthritis”, Medical Grand Rounds, University of Manitoba, March 6, 2001

 

37.            Speaker, “The NIH early synovitis cohort: studies in pathogenesis and prognosis”. Department of Internal Medicine Grand Rounds, St Boniface General Hospital, University of Manitoba March 8, 2001

 

38.            “The NIH early synovitis cohort: studies in pathogenesis and prognosis”, Diagnostic Criteria for Early Rheumatoid Arthritis (DICERA) Workshop, Vienna, AUSTRIA May 13-15, 2001

 

39.             “Prognostic markers in early synovitis, The 20th Congress of the International League of Associations for Rheumatology (ILAR) Edmonton, Alberta, Aug 26-30, 2001.

 

40.            “New insights into the pathogenesis and prognosis of early arthritis”. Intercity Rheumatology Grand Rounds, University of Toronto, Toronto ON, Jan 14, 2002

 

41.            “Autoantibodies in early rheumatoid arthritis” Diagnostic Criteria for Early Rheumatoid Arthritis (DICERA) meeting Vienna, AUSTRIA, Jan 25-27, 2002

 

42.            “Microsatellite marker analysis”.  13th  HLA Associations with Rheumatoid Arthritis:  International Histocompatibility Workshop, Victoria, BC, May 12-16, 2002

 

43.             “Improving outcomes in pain control”, Session Chair, Canadian Pain Society, Annual meeting, Winnipeg, MB  May 24, 2002

 

44.            “Targeting avb3 integrin in erosive inflammatory arthritis: bench to bedside”, Canadian Arthritis Network (CAN) theme meeting, Sherbrooke, Que, June 2, 2002

 

45.            “The value of autoantibodies in EIA/VERA”. Diagnostic criteria for early rheumatoid arthritis (DICERA) workshop Bethesda, MD USA Aug 22-24, 2002

 

46.            Invited Speaker, “Further concerns over Cox-2 Inhibitors and Bone Repair”.  Canadian Orthopaedic Residents Association, Wpg., MB (CORA) Sept 20, 2002

 

47.            Invited Speaker, “Effects of Cox-2 Inhibitors on Fracture Healing:  Clinical Implications”.  Grand Rounds, Physical Medicine and Rehabilitation, University of Manitoba, Sept 23, 2002

 

48.            “Vitaxin, a humanized monoclonal antibody, inhibits alpha V/beta3 integrin in human RA synovial tissue engrafted into SCID mice”. American College of Rheumatology (ACR) 66th Annual Scientific Meeting, Poster presentations. New Orleans, USA Oct 24-29, 2002

 

49.            “The role of hypoxia in persistent synovial inflammation”. Asthma/COPD Research Centre, Research in Progress Seminar Series, Department of Respiratory, University of Manitoba, Dec 18, 2002

 

50.            Invited speaker, “Clinical pathological correlation in early synovitis”.  Arthritis Research Retreat, University of California, San Diego, USA (UCSD) Jan 21, 2003. 

 

51.            Invited speaker “Sampling human synovial tissue:  a few lessons learnt”.  MedImmune Washington, DC  USA April 6, 2003

 

52.            External Consultant, CIHR Group in Skeletal Development and Remodeling, Group Retreat, London, ON   May 31, 2003.

 

53.            Invited Speaker “The role of hypoxia in inflammatory joint disease”., Amsterdam, NETHERLANDS, June 2, 2003

 

54.            Invited Speaker “Value of biological samples in arthritis research”.. Medac Meeting, Toronto, ON Oct.9-10 2003.

 

55.             “The effects of therapy on RA synovitis:  an integrated approach”. Canadian Arthritis Network Scientific Conference, Montreal, Quebec Nov 13-15, 2003

 

56.            Co-Chair, Research Symposium on Integrating Discovery Platforms in Autoimmune Diseases.  Toronto, ON  Dec 3-5, 2003.

 

57.            Speaker, “The role of synovial hypoxia in the pathogenesis of rheumatoid arthritis” Department of Pharmacology Research Seminar, University of Manitoba, Jan 23, 2004.

 

58.            Invited Speaker,  “Rheumatoid Arthritis: New research direction sin an enigmatic disease” Grand Rounds, University of Calgary, AB  Feb 23-24, 2004

 

59.            Invited Speaker, The International Distinguished Lecture Series in Rheumatology:  “The Great Debate: Should we be using TNFs in Early Disease”.   Toronto, ON Mar 8-9, 2004

 

60.            Participant,  “Biology of Hypoxia:  The Role of Oxygen Sensing in Development, Normal Function and Disease”, Keystone Symposia, Steamboat Springs, Colorado, USA  Mar 25-30, 2004

 

61.            Invited Speaker “Hypoxic regulation of SDF-1: A mechanism sustaining rheumatoid synovitis”, Immunology Rounds, University of Manitoba, April 22, 2004.

 

62.            Moderator, Frontiers in Inflammatory Joint Diseases Conference:  A Canadian Arthritis Research Forum.   Co-Chair Conference Steering Committee, Scientific Program Biomedical Perspectives.  Toronto, ON May 7-9, 2004.

 

63.            Invited Speaker, Arthritis Self Help Group, 25th Annual General Meeting, Winnipeg, MB May 26, 2004

 

64.            Invited Speaker “Management of Arthritis”, Section of Physical Medicine and Rehabilitation Grand Rounds, Winnipeg, MB May 31, 2004

 

65.            Moderator, “Novel Therapeutic Strategies:  Don’t miss the target”.  4th Global Arthritis Research Network (GARN) symposium. Montreal, PQ Sept. 20-22, 2004.

 

66.            Moderator, “RA treatment and gene therapy”.  American College of Rheumatology (ACR) Annual Scientific Meeting, San Antonio, TX  USA,  Oct 15-21, 2004.

 

67.            “Rheumatoid Arthritis:  Looking further upstream” Department of Internal Medicine Grand Rounds, University of Manitoba, Nov 9, 2004.

 

68.            Public lecture “A Cure for Rheumatoid Arthritis:  Can one be found within the next ten years?”, University of Manitoba, Nov 9, 2004.

 

69.            Chaired, “SRI and inflammatory joint diseases”. Canadian Arthritis Network Annual Scientific Conference, Vancouver, BC  Nov 11-14, 2004.

 

70.            Participant, Immunology Research & Development Team, “Synovial Outcomes in Adalimumab Therapy in Rheumatoid Arthritis” Research and Development Abbott Bioresearch Center Laboratories, Boston USA  Dec 15, 2004

 

71.            “What is a Coxib?”  The 3rd Canadian Consensus Conference: An evidence-based approach to prescribing NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis. University of Alberta CME program. Cambridge, ON, Invited Speaker, Jan 21-23, 2005

 

72.            Coordinator-Facilitator, Molecular Approaches to Autoimmune and Inflammatory Diseases Research Symposium University of Manitoba, Winnipeg, MB   May 19, 2005 

 

73.            Coordinated and speaker “Molecular signatures in early rheumatoid arthritis synovitis”, Research Symposium, University of Manitoba, Winnipeg, MB  May 19, 2005

 

74.            Invited Speaker, “Analysis of Rheumatoid Synovial Tissues using Immunohistology and Gene Expression Profile”. Gaithersburg, MD  USA, June 5-6, 2005 

 

75.            The American College of Rheumatology Abstract Selection Committee Meeting, Chicago, Illinois USA June 24-25, 2005

 

 

 

76.            Invited Speaker,  Rehabilitation Medicine Grand Rounds, “Management of Inflammatory Arthritis” University of Manitoba, June 27, 2005

 

77.            Lecturer, “Seronegative Arthropathies”, Internal Medicine Residents, Academic Half Day, University of Manitoba, July 5, 2005.

 

78.            Invited Speaker, American College of Rheumatology 5th Annual Summer Clinical Symposium, Santa Barbara, California USA July 21-23, 2005

 

79.            Chair, Development of National Research Initiative Meeting, Toronto, ON  August 11, 2005

 

80.            Speaker, “Early synovitis:  multiple pathways to a common clinical syndrome” 7th World Congress on Inflammation, Melbourne Australia, August 20-24, 2005

 

81.            Chair, Development of National Research Initiative Meeting, Winnipeg, MB Oct 4, 2005

 

82.            Invited Speaker, Rheumatology Rounds, “Early Rheumatoid Arthritis:  Dissecting a Complex Phenotype into Manageable Pieces” Mary Pack Arthritis Centre, Vancouver, BC October 7, 2005

 

83.            Invited Speaker, Distinguished Rheumatology Series. “ Early Rheumatoid Arthritis:  Dissecting a Complex Phenotype into Manageable Pieces”, University of Toronto, Toronto, ON Oct 24-25, 2005

 

84.            Invited Speaker, Distinguished Rheumatology Series. “Biomarkers in early RA: What does the clinician really want to know?"  University of Toronto, Toronto, ON Oct 24-25, 2005

 

85.           Chair, Panel Discussion: “Towards developing a strategic research initiative in inflammatory joint diseases:  How do we effectively integrate disciplines?” CAN Annual Scientific Conference, Gatineau, Quebec October 29-31, 2005

 

86.           Chair, Poster presentation:  CAN Strategic Research Initiative – Inflammatory Joint Diseases  - CAN Annual Scientific Conference, Gatineau, Quebec October 29-31, 2005

 

87.            Moderator – Abstract Sessions and Poster Presenter American College of Rheumatology 69th  Annual Scientific Meeting, San Diego, California USA Nov 12-17, 2005.

 

88.            Invited Speaker, “Mechanisms of Synovitis”, AstraZeneca Research and Development Meeting, England, UK, Jan 27-31, 2006

 

89.           Chair of Session, Canadian Rheumatology Association Annual Meeting, Acapulco, MEXICO, Feb 17-21, 2006

 

90.           Invited Speaker, “Searching for Novel Biomarkers in RA by Synovial Gene Expression and Proteomic Profiling.”  Osler Seminar Series in Genetics and Immunology, McGill Centre for the study of Host Resistance McGill University, Montreal, QC May 15, 2006.

 

91.           Invited Speaker, "Rheumatoid Arthritis: How does it start? Why doesn't it stop?"  Department of Internal Medicine Grand Rounds, University of Manitoba  October 3, 2006

 

92.           Invited Speaker, “Common Labs:  Indications and Interpretation”, Rheumatology Day CME, Grace Hospital, Winnipeg, MB Oct 20, 2006

 

93.           Invited Speaker, Moving Beyond Arthritis Public Conference 2006, The Arthritis Society, Winnipeg, MB Oct 20-21, 2006

 

94.           Moderator, American College of Rheumatology Annual Scientific Meeting, Washington DC USA Nov 10-15, 2006

 

95.           Invited Speaker, “Why is the prevalence of arthritis so high in First Nations People” Canadian Arthritis Network (CAN ) Annual Scientific Conference, Winnipeg, MB  Nov 30-Dec 2, 2006

 

96.           Invited Speaker, “Rheumatoid arthritis:  6 months before and 6 months after the onset” Department of Medicine,  The Rheumatology Centre, University of Western Ontario, London, ON  Dec 8, 2006

 

97.           Invited Speaker, “Research Careers in Rheumatology, Canadian Council of Academic Rheumatologists, Inaugural Rheumatology Resident’s Weekend Montreal QC Jan 26-28, 2007.

 

98.           Co-Facilitator, “Biomarkers and surrogate markers in B cell therapy”, B-Cell Summit 2007, Newport Beach, CA USA  Feb 21-23, 2007

 

99.           Invited Speaker, “Synovial Pathology”, MED 256:  Immunological Basis of Rheumatologic and Allergic Disease.  Department of Medicine, University of California, San Diego, CA   USA  April 6, 2007

 

100.         Invited Speaker, ‘Native American RA Populations”, University of Colorado, Denver, CO USA, April 9-10, 2007

 

101.         Invited Speaker, "Novel approaches to understanding the effects of targeted biological therapies", Pharmacology Rounds, University of Manitoba, May 4, 2007

 

102.         Invited Speaker, Rheumatology Rounds: “Biomarker discovery in RA synovitis”, Medical Grand Rounds: “Pre-clinical phase of rheumatoid arthritis-an etiologic study in First Nations People” and Internal Medicine Resident Seminar: “Laboratory Utilization in the Management of Rheumatic Diseases”, University of Saskatchewan, Saskatoon May 28-30, 2007.

 

103.         Invited Speaker, “Advances in the Management of Inflammatory Disease” Society of Atlantic Rheumatologists (SOAR) annual meeting June 22-24, 2007

 

104.         Invited Speaker, Rheumatology Rounds: “The synovium in early rheumatoid arthritis”, Rheumatology Fellows symposium: “Research Careers in Rheumatology” and Medical Grand Rounds: “The pre-clinical phase of rheumatoid arthritis: studies in a Native American population”, UT Southwestern Dallas October 31-November 2, 2007.

 

105.         Invited Speaker, “Biomarkers in Rheumatoid Arthritis” and “State of the Art Lecture – Immunoglobulins”, Canadian Rheumatology Association Annual Meeting, Mont Tremblant, Quebec, March 5-8, 2008.

 

106.         Invited Speaker, Rheumatology Rounds: “Biomarkers”, Evening Dinner Lecture: “First Nations and RA”, Resident and Fellow Symposium: “Biomarkers” and Teleconference: “First Nations and RA”, St. Michael’s Hospital, Toronto June 10-11, 2008.

 

107.         Invited Speaker, Intercity Grand Rounds, University of Toronto, “The preclinical stages of RA: lessons from a high risk First Nations cohort”, Toronto, Jan 13, 2009

 

108.         Invited Speaker, Rheumatology Grand Rounds, University of Washington, “The preclinical stages of RA: lessons from a high risk First Nations cohort”, Seattle, Jan 27, 2009

 

109.         Invited Speaker, Annual Congress of the Mexican College of Rheumatology, “The path to RA: lessons from a high risk First Nations cohort”, Leon, Mexico, Feb 16, 2009

 

110.         Invited Speaker, Rheumatology Grand Rounds, Barts and the London College of Medicine, London, UK, June 3, 2009

 

111.         Invited Speaker, Rheumatology Research Seminar, Leiden University, The Netherlands, “The preclinical stages of RA: lessons from a high risk First Nations cohort”, June 25, 2009

 

112.         Speaker, International Symposium on Rheumatic Diseases in Indigenous Populations: from molecules to communities: “The Pre-Clinical Phase of RA: Lessons from the Cree/Ojibway Population”, Winnipeg, Sept 25, 2009

 

113.         Invited Speaker, Annual Scientific Conference, Canadian Arthritis Network: “CAN highlights: Aboriginal Program”, Vancouver B.C., Nov 21, 2009

 

114.         Invited speaker, Rheumatology Grand Rounds, University of Calgary: “Can Rheumatoid Arthritis be prevented? studies from a high risk First Nations population”, January 27, 2010

 

115.         Invited speaker, Research Seminar, McCaig Bone and Joint Institute, University of Calgary: “Rheumatoid Synovitis: Dissecting a Complex Phenotype into Manageable Pieces”, January 27, 2010

 

116.         Invited Speaker, Rheumatology Grand Rounds, University of Western Ontario: “Can Rheumatoid Arthritis be prevented? studies from a high risk First Nations population”, March 12, 2010

 

117.         Invited Speaker, ACR Basic Research Symposium, Atlanta, GA "The earliest stage of RA in a Native American population", Nov 9, 2010

 

118.         Invited Speaker, Pre-clinical RA workshop, Amsterdam, Jan 27, 2011

 

119.         Moderator Keystone Symposium Rheumatoid Arthritis Molecular and Clinical Insights Autoimmunity II Santa Fe New Mexico Jan 2012

 

120.         Invited Speaker, Canadian Rheumatology Association/Mexican College of Rheumatology Annual scientific conference: “New RA criteria, diagnostic and prognostic biomarkers”, Cancun, Mexico, Feb 15, 2011

 

121.         Invited Speaker, Michael F. Sorrell Center for Health Science Education on the University of Nebraska Medical Center Campus: “Rheumatoid Arthritis in the North American Native Population”, Omaha, Nebraska, April 13, 2012

 

122.         Invited Speaker, JFL Woodbury Lecture, University of Halifax: “Prevention of RA:  Within our Reach”, Halifax, Nova Scotia, May 15, 2012

 

123.         Invited Speaker, Rheumatology Grand Rounds, Cedars-Sinai Hospital:  Rheumatoid Arthritis in the North American Native Population-studies in the preclinical stages of individuals at risk”.  Los Angeles, California, September 19, 2012

 

124.         Invited Speaker, “Risk for RA in First Nations Populations”, Rheumatoid Arthritis in First Nations Workshop, University of Manitoba, Winnipeg, Manitoba, October 5, 2012

 

125.         Invited Speaker, Rheumatology Grand Rounds, New York University:  Rheumatoid Arthritis in the North American Native Population-studies in the preclinical stages of individuals at risk”.  New York, New York, October 11, 2012

 

126.         Invited Speaker, American College of Rheumatology Annual Review Course:  “Setting the Stage for Rheumatoid Arthritis”, Washington DC, November 10, 2012

 

127.         Invited Speaker, American College of Rheumatology Annual Scientific Conference, Clinical Research Symposium:  “Studying Genes, Environment and Biomarkers to Identify Targets to Prevent the Onset of  Rheumatoid Arthritis”, Washington DC, November 12, 2012

 

128.         Invited Speaker, “Rheumatoid Arthritis in the North American Native (NAN) Population: studies in the preclinical stages of individuals at risk”.  Division of Clinical Immunology and Rheumatology Grand rounds, University of Alabama, Birmingham, Alabama, January 10, 2013

 

129.         Invited Speaker, “Rheumatoid Arthritis in the North American Native (NAN) Population studies in the preclinical stages of individuals at risk”. Pre-clinical RA symposium. Karolinksa Institute, Stockholm, Sweden, Jan 28, 2013

 

130.         Invited Speaker, “RA and SLE are common in Native Americans.  Management of the disease in this population is challenging”.  Columbia University, New York, May 2, 2014

 

131.         Invited Speaker, “Understanding the Pre-Clinical Stages of RA and their interactions between genes and environment that predisposes individuals/populations to RA”.  Columbia University, New York, May 2, 2014

 

132.         Invited Speaker, “CIHR’s Strategic Priorities and Directions for Musculoskeletal Research”.  Chiropractic Practice-Based Research Network (PBRN), Toronto, ON, December 6, 2014

 

133.       Invited Speaker, “The origins of RA autoimmunity:  lessons from studying Native American populations”.  Ogryzlo Day, Mount Sinai Hospital, Toronto, June 23-25, 2015